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Aim of the PhD thesis 
 
For presentation of antigen by MHC class II molecules to T cells, antigen is processed 
and loaded onto MHC II molecules in endosomal compartments of antigen presenting 
cells. There, MHC II molecules are complexed with the accessory molecules DM and 
DO. These complexes are also associated with tetraspanins, such as CD82, to form 
large supramolecular structures. It is well-known that DM serves to help loading of 
peptides onto MHC II molecules, but the function of DO is not yet clear. Likewise, 
very little is known about the biological function of CD82. 
 
It was the aim of this thesis to elucidate the role of DO and CD82 molecules in antigen 
presentation. For this study, genetically modified mice were available expressing 
different levels of DO, namely DO knock-out mice and transgenic mice over expressing 
DO. Since DO is mainly expressed in B cells, BCR transgenic mice were included, 
which internalize antigen via the BCR, resulting in efficient antigen presentation by B 
cells. In addition, the question should be answered, if DO influences antigen 
presentation differentially in early versus late endosomal compartments. 
 
For the analysis of CD82, respective knockout mice have been generated in the 
laboratory. Since nothing is known about the effects of deficient CD82 expression, first 
the phenotype of the CD82 knockout cells with regard to cell surface markers had to be 
extensively investigated. Next, the role of CD82 in proliferation of T and B 
lymphocytes and in antibody responses should be studied. Most importantly, these 
novel CD82 knockout mice allowed to investigate the long standing question whether 
or not CD82 would influence antigen presentation by MHC II molecule in the various 
endosomal loading compartments.  
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Summary 
Presentation of antigen by MHC class II molecules to CD4 T cells depends on the 
loading of antigenic peptides onto MHC class II molecules in endosomal compartments 
of antigen-presenting cells. There, efficient loading of peptides requires the assistance 
of the accessory molecule HLA-DM.  DM is found tightly associated with another 
molecule, HLA-DO in humans, or H2-O in mice, but the function of DO is not entirely 
clear. MHC class II, DM, and DO are further associated with tetraspanins such as 
CD82, but their role in antigen presentation, if any, is also not clear. In this thesis, the 
function of DO and CD82 in antigen presentation was studied. 
 
1. DO in antigen presentation.  
So far, the analysis of H2O-/- mice did not show a striking phenotype with regard to 
antigen presentation. Possible explanations are that the function of H2-O is allele-
specific and does not affect presentation by Ab MHC class II molecules, the allele 
carried by H2-O-/- mice. Moreover, only few experimental systems are available for 
thorough testing of antigen presentation by th Ab allele. In this laboratory, transgenic 
mice were generated overexpressing H2-O, designated mDO mice, which express the 
Ak allele, and for which well-studied antigen presentation systems are available. The 
study presented here shows that DO downmodulates only presentation of epitopes that 
are loaded onto Ak molecules in early endocytic compartments, but not epitopes loaded 
in late endocytic compartments. Since DO is mainly expressed in B cells which 
predominantly take up antigen via their surface immunoglobulin (BCR, B cell 
receptor), we crossed the mDO with BCR transgenic mice. Again, DO downmodulated 
presentation of antigen only in the early endocytic compartment. These data suggest 
that DO may serve to skew antigen presentation to take place preferentially in late 
compartments.  
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2. CD82 in antigen presentation. 
 
We have concentrated on the tetraspanin CD82, because CD82 was shown to be 
associated with MHC class II, DM, and DO in MHC class II loading compartments. In 
addition, CD82 is known interact with other transmembrane molecules such as TCR, 
CD4, CD8, etc.. CD82-deficient mice were generated in this laboratory for the present 
study. Expression of a large panel of surface markers was found to be unchanged in 
CD82-deficient mice. However, T cells from CD82-/- mice were hyper reactive to 
stimulation by anti-CD3 and anti-CD28 antibodies, suggesting that CD82 affects the 
TCR signalling pathway. When CD82-deficient dendritic cells were analyzed, 
decreased antigen presentation was found, but again only loading of epitopes on the 
early endocytic compartments was affected, but not loading in late compartments. 
When splenocytes were used, were most antigen-presenting cells are B cells, no 
differences between CD82-/- and wild-type cells were found with regard to antigen 
presentation. These data demonstrate for the first time a role for a tetraspanin in antigen 
presentation and suggest that CD82 enhances antigen presentation not only in a 
compartment-specific manner, but also in a cell type-specific fashion. The respective 
mechanisms need to be explored in the future. It is, however, striking to note that both 
DO and CD82 affect antigen presentation only in the early endosomal compartment. 
This may suggest a functional link between DO and CD82. 
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Zusammenfassung 
T-Helferzellen erkennen Antigene, die von MHC Classe II Molekülen präsentiert 
werden. Die Beladung von MHC Klasse II mit Peptidfragmenten von Antigenen erfolgt 
in endosomalen Kompartimenten von antigenpräsentierenden Zellen, erfordert aber die 
Mitwirkung des akzessorischen Moleküls HLA-DM. DM wiederum ist relativ fest mit 
einem anderen Molekül assoziiert, HLA-DO im Menschen, bzw. H2-O in der Maus. 
Die genaue Funktion von H2-O ist jedoch noch unklar.  MHC Klasse II, DM und DO 
sind ausserdem mit Teraspanin-Molekülen wie CD82 assoziiert, deren Rolle für die 
Antigenpräsentation noch nicht erforscht ist. In dieser Arbeit wurde die Funktion von 
DO und CD82 für Antigenpräsentation untersucht. 
 
1. DO 
Die Analyse von H2-O-/- Mäusen hat bisher keinen markanten Phänotyp in Bezug auf 
Antigenpräsentation ergeben. Eine mögliche Erklärung ist, dass H2-O allel-spezifisch 
wirkt und deshalb keinen Einfluss auf die Präsentation durch das Ab MHC Klasse II 
Molekül der H2-O-/- Mäuse hat. Eine weitere Schwierigkeit besteht darin, dass nur 
wenige experimentelle Systeme für eine umfassende Analyse der Antigenpräsentation 
durch das Ab-Allel verfügbar sind.  In unserem Labor wurden sogenannte mDO-
transgene Mäuse hergestellt, die H2-O überexprimieren und das Ak-Allel tragen, für 
welches eine Reihe von Antigenpräsentationssystemen verfügbar ist. Die Ergebnisse 
der Arbeit zeigen, dass DO die Präsentation von Antigenen negativ beeinflusst. 
Interessanterweise trifft das aber nur für Epitope zu, die in frühen endozytischen 
Kompartimenten auf Ak-Moleküle geladen werden, aber nicht für Epitope, die in späten 
endozytischen Kompartimenten geladen werden. Da DO vornehmlich in B-
Lymphozyten exprimiert ist, die Antigen hauptsächlich über ihr 
Oberflächenimmunoglobulin (BCR) aufnehmen, haben wir die mDO-Mäuse mit BCR-
transgenen Mäusen gekreuzt. Wiederum beeinflusste DO die Präsentation von Antigen 
nur im frühen endozytischen, aber nicht im späten Kompartiment. Diese Daten zeigen, 
dass DO Antigenpräsentation in späten Kompartimenten begünstigt.  
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2. CD82 
Da MHC Klasse II, DM und DO in den MHC Klasse II-Beladungskompartimenten mit 
dem Tetraspanin CD82 assoziiert vorliegt, haben wir uns auf dieses Tetraspanin 
konzentriert. Zusätzlich interagiert CD82 mit anderen Transmembranmolekülen wie 
TCR, CD4, CD8, usw.. Für die Analyse von CD82 wurden in unserem Labor knockout-
Mäuse hergestellt. Die Analyse ergab, dass die Expression einer Vielzahl von 
Oberflächenmarkern auf Lymphozyten in den CD82-/- Mäusen nicht verändert war. In 
funktionellen Untersuchungen wurden CD82-/- T-Zellen effizienter durch Antikörper 
gegen CD3 und CD28 stimuliert als CD82+/+ T-Zellen. Diese Ergebnisse zeigen, dass 
CD82 die TCR-Signalkaskade beeinflusst. Dendritische Zellen von CD82-/- Mäusen 
zeigten eine verminderte Fähigkeit zur Antigenpräsentation, aber wie im Fall von DO 
war nur das Beladen mit Epitopen in frühen endozytischen Kompartimenten betroffen, 
aber nicht in späten endozytischen Kompartimenten. Im Gegensatz zu den 
dendritischen Zellen war Antigenpräsentation in B-Lymphozyten nicht durch die 
Abwesenheit von CD82 beeinflusst.  Diese Daten zeigen zum ersten Mal, dass ein 
Tetraspanin die Präsentation von Antigen beeinflusst. CD82 unterstützt 
Antigenpräsentation nicht nur in einer kompartiment-spezifischen Weise, sondern auch 
in einer zelltyp-spezifischen Weise. Die zugrundeliegenden zellbiologischen 
Mechanismen müssen noch geklärt werden. Interessanterweise beeinflussen sowohl DO 
als auch CD82 Antigenpräsentation nur in den frühen endosomalen Kompartimenten. 
Dieses deutet auf eine funktionelle Beziehung zwischen DO und CD82 hin. 
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1.  Introduction 
 
1.1 The Immune System: An overview 
The immune system is a remarkably adaptive defense system that has evolved in 
vertebrates to protect them from invading pathogenic microorganisms. It is able to 
generate an enormous diversity of cells and molecules capable of specifically 
recognizing the large variety of foreign invaders. Functionally, an immune response can 
be divided into two related activities – recognition and response.  Furthermore, the 
system is able to discriminate between foreign molecules and the body’s own cells and 
proteins. Once a foreign organism has been recognized, the immune system enlists the 
participation of a variety of cells and molecules to mount an appropriate response, 
called an effector response, to eliminate or neutralize the foreign organism or 
substance.  Later exposure to the same foreign material induces a memory response, 
characterized by a more rapid and heightened immune reaction that serves to eliminate 
the pathogen and prevent disease [1,2]. 
 
Components of Immunity 
Immunity, the state of protection from infectious disease has both nonspecific and 
specific components.  The nonspecific component, innate immunity, is a set of disease 
resistance mechanisms that are not specific to a particular pathogen.  Phagocytic cells, 
such as macrophages, play an important role in many aspects of innate immunity.  In 
contrast, the specific component, adaptive immunity, displays a high degree of 
specificity as well as the remarkable property of memory.  The major cellular agents of 
adaptive immunity are lymphocytes. 
 
Innate Immunity 
Innate immunity can be seen to comprise four types of defensive barriers: anatomic 
(skin, mucous membranes), physiologic (temperature, low pH), Phagocytic 
((macrophages, neutrophils, blood monocytes), and inflammatory (tissue damage and 
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infection induce leakage of vascular fluid, containing serum proteins with antibacterial 
activity). 
 
Adaptive Immunity 
Adaptive immunity is capable of recognizing and selectively eliminating specific 
foreign microorganisms and molecules.  Unlike innate immune responses, adaptive 
immune responses are reactions to specific antigenic challenges and display four 
characteristic attributes:  Antigen specificity, Diversity, Immunologic Memory, and 
Self/Nonself recognition. 
 
Innate and adaptive immunity do not operate in total independence of each other.  They 
cooperate in important ways to produce more effective immunity.  The adaptive 
immune system produces signals and components that stimulate and increase the 
effectiveness of innate responses.  More detailed explanation on this cross talk can be 
found in the following chapters. 
 
1.1.1a Cells of the immune system 
B cells 
Its designation stems from its site of maturation, bursa of Fabricius in birds; bone 
marrow in a number of mammalian species, including humans and mice.  B cells can be 
distinguished from other lymphocytes by their synthesis and display of membrane 
bound immunoglobulin (antibody) molecules, which serve as receptors for antigen 
(BCR).  According to the clonal selection theory an individual B cell express 
membrane receptors that are specific for a distinct antigen.  Each of the approximately 
1.5x105 antibody molecules on the membrane of a single B cell has an identical binding 
site for antigen.  The diversity in the generation of pre determined antigen specific B 
cell receptors are possible because of the RAG 1 and RAG 2 gene products, which are 
essential for VDJ recombination. The potential number of antibodies of distinct 
sequences that the mammalian immune system is capable of generating is extremely 
high and exceeds 1x1010. Among the major other molecules expressed on the 
membrane of mature B cells are the following: IgM, IgD, B220 (CD45R), Class I&II 
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MHC, CD21 (CR2), CD35(CR1), Fcγ RII (CD32), CD80(B7-1), CD86(B7-2), and 
CD40. 
 
T cells 
T lymphocytes derive their name from their site of maturation in the thymus.  T cells 
express T cell receptor (TCR), structurally distinct from immunoglobulin, most notably 
in the structure of its antigen binding site.  The TCR does not recognize free antigen.  
Instead, the TCR recognizes only antigen that is bound to major histocompatibility 
complex (MHC) molecules.  Fundamental differences between the humoral and cell 
mediated branches of the immune system is that the B cell is capable of binding soluble 
antigen, whereas the T cell is restricted to binding antigen displayed on self cells 
(antigen presenting cells).  T cells that express the membrane glycoprotein molecule 
CD4 are restricted to recognizing antigen bound to class II MHC molecules, whereas T 
cells expressing CD8, a dimeric membrane glycoprotein, are restricted to recognition of 
antigen bound to class I MHC molecules.  CD4+ T cells generally function as T helper 
(TH) cells and are class II restricted; CD8+ T cells generally function as T cytotoxic 
(TC) cells and are class I restricted.  The ratio is approximately 2:1 in humans, but it 
may alter significantly in various disease conditions. T helper cell secretes various 
cytokines upon activation after the recognition of antigen presented by MHC II 
molecule.  Changes in the pattern of cytokines produced by T helper cells can change 
the type of immune response that develops among other leukocytes.  The TH1 response 
produces a cytokine profile that supports inflammation and activates mainly certain T 
cells and macrophages, whereas the TH2 response activates mainly B cells and immune 
responses that depend upon antibodies.  The potential number of TCR of distinct 
specificity that the mammalian immune system is capable of generating is extremely 
high and exceeds 1x1012.Another subpopulation of T lymphocytes called regulatory T 
cells (Treg), which suppress the auto reactive effector T cells. The mechanism of Treg 
function is not completely understood. 
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Dendritic Cells (DCs) 
The dendritic cell acquired its name because it is covered with maze of long membrane 
extensions that resembles the dendrites of nerve cells.  Most dendritic cells process and 
present antigen to TH cells.  These cells can be classified by their location:  Langerhans 
cells found in the epidermis and mucous membranes, Interstitial Dendritic cells, which 
populate most organs, Interdigitating dendritic cells present in T cell areas of secondary 
lymphoid tissue and the thymic medulla, Circulating dendritic cells include those in the 
blood, which consists of 0.1% of the blood leukocytes, and those in the lymph (known 
as veiled cells).  The dendritic cells in different locations have different forms and 
functions.  Despite their differences, all of these dendritic cells constitutively express 
high levels of both class I and class II MHC molecules and members of the co-
stimulatory B7 family.  DCs are the most important antigen presenting cells in the 
body.  They will be discussed again in the section on antigen presentation.  
 
Another type of dendritic cell, the follicular dendritic cell (FDC), appears to have a 
different origin and function from the antigen presenting dendritic cells.  FDC do not 
express class II MHC and therefore do not function as antigen presenting cells for TH 
cell activation.  FDC express high levels of Fc receptors for antibody and complement 
receptors.  Antigen antibody complexes on FDC can be retained for very long periods 
of time ranging from weeks to months or even longer.  FDC play a very important role 
in germinal center reactions in the spleen [1,2].   
 
Other Immune Cells: 
In the innate immune system, there exist several additional cell types with important 
functions, such as NK cells, macrophages, mast cells, granulocytes and neutrophils.  
These cell types will not be described further here. 
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1.1.1b Organs of the Immune System 
Thymus 
The thymus is a flat, bilobed organ situated above the heart.  Each lobe is organized 
into two compartments:  the outer compartment or cortex is densely packed with 
immature T cells called thymocytes, whereas the inner compartment or medulla is 
sparsely populated with thymocytes.  T cell precursors migrate from bone marrow to 
thymus for the selection process.  Thymic stromal cells which express high levels of 
class I and class II MHC molecules, play a critical role in the selection process of 
thymocytes. Developing thymocytes that are unable to recognize self MHC molecules 
or that do have high affinity for self antigen plus self MHC (or self MHC alone) are 
eliminated by programmed cell death specifically termed as apoptosis.  Thus, only 
those cells whose receptors recognize a self MHC molecule plus foreign antigen are 
allowed to mature.  An estimated 95-99% of all thymocytes progeny undergo apoptosis 
within the thymus without ever maturing.  Thymectomized mice show a dramatic 
decrease in circulating lymphocytes of the T cell lineage and an absence of cell 
mediated immunity.  Aging is accompanied by a decline in thymic function.  This may 
be one of the reasons for the development of autoimmune disorders in aged people [2]. 
 
Bone Marrow 
The bone marrow is a central site for hematopoiesis as explained previously.   B cells 
are produced in the bone marrow throughout life, but very few of those mature.  There 
are several developmental stages during the development of B cells in bone marrow; 
pro-B cells, pre-B cells, immature B cells and mature B cells.  It is estimated that in 
mice the bone marrow produces about 5x107 B-cells/day but only 5x106 (about 10%) 
actually are recruited into the recirculating B cell pool.  The remaining 90% cells will 
undergo apoptosis without ever leaving the bone marrow.  Like during thymic selection 
a selection process occurs within bone marrow eliminating B cells with self reactive 
antibody receptors [2]. 
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Lymphatic System 
When blood circulates under pressure, its fluid component seeps through the thin wall 
of the capillaries into the surrounding tissue, called lymph.  Lymph flows from the 
spaces in connective tissue into a network of tiny open lymphatic capillaries and then 
into a series of progressively larger collecting vessels called lymphatic vessels. The 
largest lymphatic vessel, the thoracic duct, empties into the left subclavian vein near the 
heart.  In this way, the lymphatic system captures fluid lost from the blood and returns 
it to the blood, thus ensuring steady state levels of fluid within the circulatory system.  
The heart does not pump the lymph through the lymphatic system; instead the flow of 
lymph is achieved as the lymph vessels are squeezed by movements of the body’s 
muscles.  A series of one way valves along the lymphatic vessels ensures that lymph 
flows only in one direction.  When a foreign antigen gains entrance to the tissues, it is 
picked up by the lymphatic system (which drains all the tissues of the body) and is 
carried to various organized lymphoid tissues such as lymph nodes, which trap the 
foreign antigen.  As lymph passes from the tissues to lymphatic vessels, it becomes 
progressively enriched in lymphocytes.  Thus the lymphatic system also serves as a 
means of transporting lymphocytes and antigen from the connective tissues to 
organized lymphoid tissues where the lymphocytes may interact with the trapped 
antigen and undergo activation [2]. 
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   Fig.: 1a  The Human Lymphatic System                           Fig.: 1b  Lymphatic Vessels [2] 
 
1.1.2 Secondary Lymphoid Organs 
Various types of organized lymphoid tissues are located along the vessels of the 
lymphatic system.  Lymph nodes and spleen are the most highly organized of the 
secondary lymphoid organs; they comprise not only lymphoid follicles, but additional 
distinct regions of T cell and B cell activity and they are surrounded by a fibrous 
capsule.  Less organized lymphoid tissue, collectively called mucosal associated 
lymphoid tissue (MALT), is found in various body sites.  MALT includes Peyer’s 
patches, the tonsils and the appendix, as well as numerous lymphoid follicles within 
lamina propria of the intestine and in the mucous membranes lining the upper airways, 
bronchi, and genital tract.  In a severe infection conditions, ectopic germinal centers can 
be formed any where in the body to make an interface between antigen presenting cell 
and T cell, in order to eliminate the pathogen from body rapidly [2]. 
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Lymph Nodes 
Morphologically, a lymph node can be divided into three roughly concentric regions: 
the cortex, the paracortex, and the medulla.  The outermost layer, the cortex contains 
lymphocytes (mostly B cells), macrophages, and follicular dendritic cells arranged in 
primary follicles.  After antigenic challenge, the primary follicles enlarge into 
secondary follicles, each containing a germinal center. Beneath the cortex is the 
paracortex, which is populated largely by T cells and also contains interdigitating 
dendritic cells thought to have migrated from tissues to the node.  These interdigitating 
dendritic cells express high levels of class II MHC molecules, which are necessary for 
presenting antigen to TH cells.  The innermost layer of a lymph node, the medulla is 
more sparsely populated with lymphoid lineage cells; of those present, many are plasma 
cells actively secreting antibody molecules.  Afferent lymphatic vessels pierce the 
capsule of a lymph node at numerous sites and empty lymph into the subcapsular sinus 
and lymph comes out of the node through efferent lymphatic vessel. 
         
Fig.: 2 Structure of the Lymph Node [2]. 
Spleen 
The spleen is a large, ovoid secondary lymphoid organ situated high in the left 
abdominal cavity.  While lymph nodes are specialized for trapping antigen from local 
tissues, the spleen specializes in filtering blood and trapping blood borne antigens; thus, 
it can respond to systemic infections.  Unlike lymph nodes, the spleen is not supplied 
by lymphatic vessels.  Instead, blood borne antigens and lymphocytes are carried into 
the spleen through the splenic artery.   
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More recirculating lymphocytes pass daily through the spleen than through all the 
lymph nodes combined.  The spleen is surrounded by a capsule that extends a number 
of projections (trabeculae) into the interior to form a compartmentalized structure.  The 
compartments are of two types, the red pulp and white pulp, which are separated by a 
diffuse marginal zone.  The splenic red pulp consists of a network of sinusoids 
populated by macrophages and numerous red blood cells, it is the site where old and 
defective red blood cells are destroyed and removed.  Many of the macrophages within 
the red pulp contain engulfed red blood cells.  The splenic white pulp surrounds the 
branches of the splenic artery, forming a periarteriolar lymphoid sheath (PALS) 
populated mainly by T cells.  The marginal zone located peripheral to the PALS, is rich 
in B cells organized into primary lymphoid follicles.  The effect of splenectomy on the 
immune response depends on the age at which the spleen is removed.  In children, 
splenectomy often leads to an increased incidence of bacterial sepsis, whereas in adults 
it has less adverse effects, although it leads to some increase in blood borne bacterial 
infections (bacteremia) [2]. 
 
1.2 Antigen Presentation 
Recognition of foreign antigen by a T cell requires that peptides derived from the 
antigen be displayed within the cleft of an MHC molecule on the membrane of a cell.  
The formation of these peptide-MHC (pMHC) complexes requires that a protein 
antigen to be degraded into peptides by a sequence of events called antigen processing.  
The degraded peptides then associate with MHC molecules within the cell interior, and 
the pMHC complexes are transported to the membrane, where they are displayed 
(antigen presentation).  Class I MHC molecules bind peptides derived from endogenous 
antigens that have been processed within the cytoplasm of the cell.  Class II MHC 
molecules bind peptides derived from exogenous antigens that are internalized by 
phagocytosis or endocytosis and processed within the endocytic pathway.  
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            Fig.: 3a Cytosolic Pathway                                         3b Endocytic Pathway [2] 
 
1.2.1 Major Histocompatibility Complex 
The molecular center of the immune system consists of major histocompatibility 
complex (MHC) molecules: the cell surface receptors that govern, by interaction with 
membrane expressed molecules on crucial cells of the innate and adaptive immune 
systems.  Work carried out in the 1940s by Peter Gorer and George Snell established 
that antigens encoded by the genes in the group designated II took part in the rejection 
of transplanted tumors and other tissue.  Snell called these genes “histocompatibility 
genes”; their current designation as histocompatibility-2 (H-2) genes was in reference 
to Gorer’s group II blood group antigens.  Gorer died before his contributions were 
recognized fully, Snell was awarded the Nobel Prize in 1980 for this work.  The MHC 
is a set of linked genes, located on chromosome 6 of the human, chromosome 17 of the 
mouse.  The MHC molecules are not static surface receptors that merely bind another 
set of receptors to indicate their presence and number.  They are structurally and 
conformationally dynamic: they modulate their structure by incorporating peptides 
derived from ingested foreign molecules or dysregulated proteins expressed in the same 
cell.  Members of the family of MHC encoded molecules interact extensively with a 
number of other molecules, during both their biosynthesis and intracellular trafficking.  
These interactions regulate the quality and rate of their appearance in specialized 
intracellular compartments as well as their arrival at the cell surface.  The MHC is 
referred to as the HLA complex in humans and as the H-2 complex in mice.  Although 
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the arrangement of genes is somewhat different, in both cases the MHC genes are 
organized into regions encoding three classes of molecules: 
 
• Class I MHC genes encode glycoproteins expressed on the surface of nearly all 
nucleated cells; the major function of the class I gene products is presentation of 
peptide antigens to TC cells.   
 
• Class II MHC genes encode glycoproteins expressed primarily on antigen 
presenting cells (macrophages, dendritic cells, and B cells), where they present 
processed antigenic peptides to TH cells.   
 
• Class III MHC genes generally encode various secreted proteins that have 
immune functions, including components of the complement system and 
molecules involved in inflammation. 
 
Structure of Class II MHC Molecules 
Class II MHC molecule contain two different polypeptide chains, a 33kDa alpha chain 
and a 28kDa beta chain, which associated by noncovalent interactions.  Class II MHC 
molecules are membrane bound glycoproteins that contain external domains, a 
transmembrane segment, and a cytoplasmic anchor segment.  Each chain in a class II 
molecule contains two external domains: α1 and α2 domains in one chain and β1 and 
β2 domains in the other.  The membrane proximal α2 & β2 domains bear sequence 
homology to the immunoglobulin fold structure (for this reason, class II MHC 
molecules also are classified in the immunoglobulin superfamily).  The membrane 
distal portion of a class II MHC molecule is composed of the α1 & β1 domains and 
forms the antigen binding cleft for processed antigen.  The two chains of the class II 
MHC molecules are encoded by the: I-A and I-E regions in mice and by the DP, DQ 
and DR regions in humans.  MHC genes are highly polymorphic, meaning that many 
alternative forms of the gene or alleles exist at each locus.  MHC class I molecules 
consist of a α-chain containing these domains: α1, α2, and α3 and the associated β2 
microglobulin [1,2,7].  
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Fig.: 4 Schematic diagrams of Class I and Class II MHC molecules [2] 
Peptide binding by MHC Molecules 
Several hundred different allelic variants of class I and II MHC molecules have been 
identified in humans.  Any one individual, however, expresses only a small number of 
these molecules- up to 6 different class I molecules and up to 12 different class II 
molecules.  Yet this limited number of MHC molecules must be able to present an 
enormous array of different antigenic peptides to T cells, permitting the immune system 
to respond specifically to a wide variety of antigenic challenges.  Thus peptide binding 
by class I and II molecules does not exhibit the fine specificity characteristic of 
antibodies and T cell receptors.  Instead, a given MHC molecule can bind numerous 
different peptides, and some peptides can bind to several different MHC molecules.  
The peptide binding groove in class I molecule is blocked at both ends, whereas the 
groove is open in class II molecules.  As a result of this difference, class I molecules 
bind peptides that typically contain 8-10 amino acid residues, while the open groove of 
class II molecules can accommodate slightly longer peptides of 13-18 amino acid 
residues.  Another difference is that class I binding requires that the peptide contain 
certain amino acid residues, called anchor residues, near the N and C terminal ends; 
there is no such requirement for class II peptide binding.  The KD value for the peptide 
MHC molecule complex is approximately 10-6; the rate of association is slow, but the 
rate of dissociation is even slower.  This means, the peptide MHC molecule association 
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is very stable under physiologic conditions, thus most of the MHC molecules expressed 
on the membrane of a cell will be associated with a peptide of self or nonself origin.   
 
MHC and Immune Responsiveness 
Early studies by B. Benacerraf in which guinea pigs were immunized with simple 
synthetic antigens first showed that the ability of an animal to mount an immune 
response, as measured by the production of serum antibodies, is determined by its MHC 
haplotype [3].  Later experiments by H. McDevitt, G.J. Hämmerling and M. Sela used 
congenic and recombinant congenic mouse strains to map the control of the so called 
immune response genes to the class II MHC.  By analyzing the products of these Ir or 
immune response genes, molecules were discovered by McDevitt and Hämmerling that 
we call today MHC class II molecules.  We now know that the dependence of immune 
responsiveness on the class II MHC reflects the central role of class II MHC molecules 
in presenting antigen to TH cells [4-6]. 
 
1.2.2 MHC Restriction of T cells 
Both CD4+ and CD8+ T cells can recognize antigen only when it is presented with a self 
MHC molecule on the membrane of antigen presenting cell.  This attribute, called self-
MHC restriction.  The self MHC restriction of CD8+ T cells was first demonstrated by 
R. Zinkernagel and P. Doherty in 1974.  In their experiments, mice were immunized 
with lymphocytic choriomeningitis (LCM) virus; several days later, the animals’ spleen 
cells, which included TC cells killed only syngeneic virus infected target cells.  Later 
studies with congenic and recombinant congenic strains showed that the TC cell and the 
virus infected target cell must share class I molecules encoded by the same haplotype.  
Thus, antigen recognition by CD8+ TC cells is class I MHC restricted.  In 1996, they 
were awarded Nobel Prize for their contribution to the understanding of cell mediated 
immunity [1,2,11].   
 
A. Rosenthal and E. Shevach showed that antigen specific proliferation of TH cells 
occurred only in response to antigen presented by macrophages of the same MHC 
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haplotype[10, 11].  Together with McDevitt studies these experiments confirmed that 
the antigen recognition by CD4+ TH cell is class II MHC restricted [2,10]. 
 
1.3 Antigen Processing and Presentation Pathways 
Early evidence for the necessity of antigen processing was obtained from the 
experiments conducted by K. Ziegler and E.R. Unanuae [12].  They contradicted the 
prevailing dogma that antigen recognition by B and T cells was basically similar.  
These researchers observed that TH cell activation by bacterial protein antigens was 
prevented by treating the antigen presenting cells with paraformaldehyde prior to 
antigen exposure.  However, if the antigen presenting cells were allowed to ingest the 
antigen and were fixed with paraformaldehyde 1-3 hr later, TH cell activation still 
occurred.  During the interval of 1-3 hr, the antigen presenting cells had processed the 
antigen and had displayed it on the membrane in a form able to activate T cells.   
 
Three cell types are classified as professional antigen presenting cells; dendritic cells, 
macrophages and B lymphocytes.  These cells differ in their mechanisms of antigen 
uptake, in whether they constitutively express class II MHC molecules, and in their co-
stimulatory activity: 
 
• Dendritic cells are the most effective of the antigen presenting cells.  Because 
they constitutively express a high level of class II MHC molecules and co-
stimulatory activity, they can activate naïve TH cells. 
 
• Macrophages must be activated by phagocytosis of microorganisms before they 
express class II MHC molecules or the co-stimulatory B7 molecules. 
 
• B cells constitutively express class II MHC molecule but must be activated 
before they express the co-stimulatory B7 molecules. 
 
Several other cell types (Thymic epithelial cells, vascular endothelial cells, Fibroblasts, 
Glial cells, Pancreatic beta cells, Thyroid epithelial cells), classified as non professional 
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antigen presenting cells, can be induced to express class II MHC molecules.  Many of 
these cells function in antigen presentation only for short periods of time during a 
sustained inflammatory response. 
 
Evidence for Two Processing and Presentation Pathways 
Intracellular (endogenous) and extracellular (exogenous) antigens present different 
challenges to the immune system.  Extracellular antigens are eliminated by secreted 
antibody, whereas intracellular antigens are most effectively eliminated by cytotoxic T 
lymphocytes (CTLs).  To mediate these responses, the immune system uses two 
different antigen presenting pathways: endogenous antigens are processed in the 
cytosolic pathway and presented on the membrane by class I MHC molecules; 
exogenous antigens are processed in the endocytic pathway and presented on the 
membrane by class II MHC molecules [13,-15].   
 
1.3.1 The Cytosolic Pathway 
The pathway by which endogenous antigens are degraded for presentation with class I 
MHC molecules utilizes pathways involved in the normal turnover of intracellular 
proteins.  In eukaryotic cells protein levels are carefully regulated.  Every protein is 
subject to continuous turnover and is degraded at a rate that is generally expressed in 
terms of its half life.  Some proteins have very short half life (for example transcription 
factors); denatured, misfolded or abnormal proteins also are degraded rapidly.  
Intracellular proteins are degraded into short peptides by a cytosolic proteolytic system 
present in all cells. Proteins targeted for proteolysis often tagged with ubiquitin, a small 
protein.  Ubiquitin-protein conjugates can be degraded by a multifunctional protease 
complex called a proteasome.  Each proteasome is a large (26S), cylindrical particle 
consisting of four rings of protein subunits with a central channel of 10-50 Ǻ.  A 
proteasome can cleave peptide bonds between 2 or 3 different amino acid combinations 
in an ATP dependent process.  Degradation of ubiquitin-protein complexes is thought 
to occur within the central hollow of the proteasome, thereby preventing lysis of other 
proteins within the cytoplasm.  The immune system appears to modify the proteasome 
by the addition of two subunits to the proteasome: LMP2 and LMP7 [2].  These 
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subunits are encoded within the MHC gene cluster and are induced by increased levels 
of IFN-γ. 
 
Fig.: 5 Generation of antigenic peptide class I MHC complexes in the Cytosolic Pathway [2] 
 
Peptide Transport from the Cytosol to the ER 
The transporter protein, designated TAP (for transporters associated with antigen 
processing) is a membrane spanning heterodimer consisting of two proteins: TAP1 and 
TAP2.  In addition to their multiple transmembrane segments, the TAP1 and TAP2 
proteins each have one hydrophobic domain, which is thought to project through the 
membrane into the lumen of the ER, and on ATP binding domain, which projects into 
the cytosol.  Both TAP1 and TAP2 belong to the family of ATP binding cassette 
proteins, these proteins mediate ATP dependent transport of peptides.  Peptides 
generated in the cytosol by the proteasome are translocated by TAP into the ER.  TAP 
has the highest affinity for peptides containing 8-13 amino acids, which is the optimal 
peptide length for class I MHC binding.  The calnexin associated class I MHC α chain 
binds to β2 microglobulin, dissociates from calnexin and binds to calreticulin and to 
tapasin, which is associated with the transmembrane TAP protein (ERp57 may be 
involved at this step).  This class I MHC complex then captures an antigenic peptide, 
which allows dissociation of the MHC-peptide complex from the chaperones.  Finally, 
the peptide loaded class I MHC molecule is transported from the ER through the Golgi 
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complex to the plasma membrane.  Studies from the tapasin knockout (KO) mice, 
ERp57 knockout mice and TAP knockout mice shows that reduced class I MHC 
expression on the cell surface.  The extent of reduction of class I MHC with TAP KO 
mice is severe than tapasin KO and ERp57 KO.  It suggests that loading complex 
members for class I MHC are very important not only for optimal peptide binding but 
also for the stability of the class I MHC [16-19]. 
 
1.3.2 Exogenous Pathway 
Antigen presenting cells can internalize antigen by phagocytosis, endocytosis or both.  
Macrophages internalize antigen by both processes, whereas most other APCs are not 
phagocytic or poorly phagocytic and therefore internalize exogenous antigen only by 
endocytosis (either receptor mediated endocytosis or pinocytosis).  B cells, for 
example, internalize antigen very effectively by receptor mediated endocytosis using 
specific membrane antibody as the receptor.   
 
Peptide Generation in Endocytic Vesicles 
Once an antigen is internalized, it is degraded into peptides within compartments of the 
endocytic processing pathway.  The endocytic pathway appears to involve increasingly 
acidic compartments: early endosomes (pH 6-6.5); late endolysosomes (pH 4.5-5).  
Internalized antigen moves from early to late endosomes, encountering hydrolytic 
enzymes and a lower pH.  Lysosomes contain a unique collection of more than 40 acid-
dependent hydrolases, including proteases, nucleases, glycosidases, lipases, 
phospholipases and phsphatases.  Within the compartments of the endocytic pathway, 
antigen is degraded into oligopepties of about 13-18 amino acid residues, which bind to 
class II MHC molecules [19]. 
 
Transport of Class II MHC Molecules to Endocytic Vesicles 
Since antigen presenting cells express both class I and class II MHC molecules, some 
mechanism must exist to prevent class II MHC molecules from binding to the same set 
of antigenic peptides as the class I molecules.  When a class II MHC molecule is 
synthesized within the ER, it associates with another protein called the invariant (Ii) 
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chain.  Three pairs of the class II αβ chains associate with a preassembled invariant 
chain trimer.  This trimeric protein interacts with the peptide-binding cleft of the class 
II molecule, preventing endogenously derived peptides and peptides from binding to 
the cleft while the class II molecule is within the ER.  In addition to its role in 
preventing peptide or protein binding to class II MHC molecules [62], the invariant 
chain is also involved in the folding of the class IIα and β chains, their exit from the 
ER, and the subsequent routing of class II molecules to the endosomal compartments.  
The invariant chain contains sorting signals in its cytoplasmic tail that directs the 
transport of the class II MHC complex from the trans-Golgi network to the endocytic 
compartments [8]. 
 
Assembly of Peptides with Class II MHC Molecules 
Class II MHC-invariant chain complexes are transported from ER through Golgi 
complex and trans-Golgi network to endosomes.  As the proteolytic activity increases 
in endosomes the invariant chain is gradually degraded.  However, a short fragment of 
the invariant chain termed CLIP (for Class II associated invariant chain peptide) 
remains bound to the class II molecule.  CLIP physically occupies the peptide binding 
groove of the class II MHC molecule, presumably preventing and premature binding of 
antigenic peptide.  A nonclassical class II MHC molecule, called HLA-DM (H2-M in 
mouse) (“DM”), plays a role in the removal of CLIP and in the subsequent loading of 
class II molecules with antigenic peptides.  
 
DM – Catalyst, Chaperone and Peptide Editor 
H2-M markedly enhances the release of CLIP, thereby accelerating the loading of class 
II molecules with cognate peptide.  DM mediated peptide exchange follows the rules of 
Michaelis-Menten kinetics derived from enzyme catalysis, which suggests that DM acts 
like a catalyst.  As indicated by both biochemical analysis and the crystal structure, DM 
cannot bind antigenic peptides, and is therefore unlikely to act as a peptide transfer 
molecule.  Catalysis occurs at substoichiometric amounts compatible with a DM:HLA-
DR ratio of about 1:5 in loading compartments.  In agreement with the notion that 
peptide loading occurs mainly in acidic endo-lysosomal compartments, DM mediated 
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peptide exchange is most efficient at the low pH of these organelles (pH 4.5-5).  After 
CLIP release, DM stabilizes the intermediate empty MHC class II molecules, which 
otherwise would denature and aggregate at low pH in the absence of a stabilizing 
peptide in their binding groove.  This property is regarded as a chaperone function of 
DM.  Under steady state conditions, about 20-25% of DR in loading compartments 
exists in empty and highly peptide receptive DM-DR complexes that enable the cell to 
respond rapidly to an antigenic challenge.  Importantly, DM not only exchanges CLIP 
for cognate peptide but also exchanges low stability peptides (with a high off rate) for 
peptides that bind class II molecules more stably (peptides with a low off rate).  Thus, 
DM acts as a peptide editor, and thereby favors the formation of stable MHC class II 
peptide complexes so that CD4+ T cells have more time to screen antigen presenting 
cells for their protein content [20-25]. 
 
Conformational alterations of DR molecules imposed by DM 
Class II molecules undergo conformational changes during maturation and loading.  
Some of these changes appear to be controlled by DM.  For example, DR3-CLIP 
molecules do not react with the DR3 specific 16.23 antibody, but association with DM 
results in an empty DR3-DM intermediate, which has switched to a 16.23+ 
conformation that is conserved after loading with cognate peptide.  In the absence of 
DM, CLIP can also be exchanged for peptide through an allele specific self release 
mechanism of CLIP, but in this situation the resulting DR3 peptide complex remains 
16.23-.  Notably, T cells can discriminate between the 16.23+ and 16.23- isoforms of 
DR3-peptide complexes.  Thus conformational changes imposed by DM seem to be 
relevant to T cell recognition [31,32]. 
 
Peptide editing by DM in recycling compartments and at the cell 
surface 
DM is known to exert its function mainly in late endosomal compartments, but it has 
been shown that the small amount of DM (about 10% of total DM) that can be found at 
the surface of B cells and immature dendritic cells also has a role.  Surface DM 
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enhances the binding of exogenously added high stability peptide and decreases binding 
of low stability peptide.  Interestingly, DM has been shown to counteract the 
presentation to T cells of myelin basic protein – an autoantigen implicated in multiple 
sclerosis that is loaded onto class II molecules at the cell surface and in the recycling 
compartment.  Thus, DM acts also as a peptide editor at the cell surface and in 
recycling compartments.  The implication of these findings is that disturbances of DM 
expression or activity may influence initiation and progression of autoimmune diseases 
[34].  
 
Quality control model for DM 
The available data are compatible with the following quality control model.  The 
peptide binding groove of MHC class II molecules is in equilibrium between two 
principal conformational states: an open and a more closed state.   
 
Fig.: 6 Functions of DM as Catalyst, Chaperone and Peptide Editor [31] 
The preferential binding of DM to class II molecules that are empty or occupied with 
low stability peptides suggests that DM has a higher affinity for a more open 
conformation.  Thus, binding of DM may shift the equilibrium towards a more open 
binding groove, probably breading conserved hydrogen bonds between the peptide 
backbone and MHC class II side chains, and thereby enabling the peptide, or CLIP to 
dissociate.  Stably binding peptides would be able to force the groove into the closed 
state with concomitant dissociation of DM, allowing DM to engage another class II – 
CLIP complex [36-37].  If there is an abundance of low stability peptides, then these 
can bind but may be exchanged for a high stability peptide.  Glycin and proline residues 
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at peptide anchor and non anchor positions have been identified as residues that 
decrease MHC class II complex stability and increase susceptibility to DM mediated 
release.  This quality control model is consistent both with the kinetic identification of 
class II intermediates that are highly receptive to peptides and with empty DM-DR 
complexes observed in loading compartments.  This model also explains the 
preferential, but not exclusive, loading with stably binding peptides that occurs in the 
presence of DM.  Mutagenesis studies have mapped the interaction site with DM to the 
lateral face of DR3 molecules.   
 
The function of DM is modulated by DO (HLA-DO in humans, H2-O in mouse), 
another non classical MHC molecule.  In addition to DO it may be influenced by 
tetraspanin molecules such as CD82 and CD63, which appear to form large complexes 
with class II and DM molecules [31,33].   
 
HLA-DO/H2-O: a modulator of DM 
HLA-DO/H2-O molecules are MHC class II like heterodimers encoded in the MHC.  
Like DM, they display limited polymorphism and do not bind peptides.  DO is 
expressed mainly in B cells and some thymic epithelial cells, but its low expression has 
also been reported in dendritic cells.  In B cells, DO is stably complexed with DM 
during intracellular transport and in endo/lysosomal compartments, and recycles 
between MHC loading compartments and the cell surface.  In fact DO require 
association with DM to leave the ER.  It has been reported that germinal center B cells 
express reduced levels of DO, thereby DM to DO ratio substantially increases, which is 
a favorable situation for the germinal center B cells to take up the antigens displayed on 
the surface of follicular dendritic cells for the presentation to a TH cell to get the help 
for the formation of memory B cells and plasma cells. The strong association and co-
localization of DO with DM in loading compartments suggests that DO may have a role 
in modulating the functions of DM [31]. 
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Influence of DO on MHC class II antigen Presentation 
The function of DO has been a matter of debate.  Over expression of DO in various cell 
lines has led to accumulation of DR-CLIP complexes at the cell surface in some 
studies; however, another study reports a decrease in surface DR-CLIP complexes.  By 
contrast, no change in the numbers of class II CLIP complexes was found in engineered 
mice or murine B cell lines expressing different levels of DO.  These conflicting results 
may reflect experimental artifacts in transfectants expressing non physiological 
amounts of DO, or differences between species, cell types or class II alleles.  Cell 
transfectants, or transgenic or knockout mice expressing different levels of DO 
consistently show that DO down modulates presentation of several antigens to T cells 
in the context of different MHC class II alleles.  Interestingly, this down modulatory 
activity of DO is observed only when the antigen is taken up via fluid phase 
endocytosis.  In the case of antigen up take via the B cell receptor (BCR), presentation 
of some (but not all) antigens or epitopes is enhanced by DO.   
 
Fig.: 7  Role of H2-O/HLA-DO in antigen presentation 
BCRs are likely to transport antigen into late compartments; by contrast, during fluid 
phase uptake the antigen can be processed and loaded in all the compartments along the 
endocytic pathway.  Thus, DO seem to enhance loading in late compartments, but may 
decrease loading in early endosomes.   This conclusion is supported by experiments 
with purified proteins, indicating that DO favors peptide loading at pH4.5-5.0, and 
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appears to reduce loading at pH6.0-6.5.  But loading was not decreased by DO at pH6 
in another study.  The nature of the DO preparation or the peptide used might account 
for the differences.  In comparison to DM alone, DM-DO complexes seem to bind more 
tightly to DR and are more efficient stabilizers of empty DR molecules at acidic pH.  
This explains the enhancement of peptide loading by DO at low pH, but not the 
inhibitory property of DO at high pH.  Any model on the physiological role of DO must 
explain why DO is predominantly expressed in professional antigen presenting cells, B 
cells and DCs but not in macrophages [31,38-40]. 
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1.4 Biology of Tetraspanin Proteins 
 
The cell membrane contains many different cell surface proteins, some in motion, and 
some anchored to the cytoskeleton. Which execute different tasks (signaling, adhesion, 
etc.).  Considerable evidence emerging out during the recent times suggests that the 
membrane molecules are arranged in rafts or microdomains.  Here tetraspanins seem to 
be important for such organization. Their ability to interact with many other signaling 
molecules and participate in activation, adhesion, and cell differentiation could all 
relate to role as molecular facilitators that bring together large molecular complexes 
and allow them, through stabilization, to function more efficiently. The tetraspanin 
superfamily was first recognized in 1990, when comparison of the sequences of the 
newly cloned CD37, CD81 (TAPA-1), and sm23 genes with the tumor associated gene 
CD63 revealed sequence homology and a conserved predicted structure.  The family 
has now grown to about 32 members in mammals, 35 in flies and 20 in worms.  
Individual tetraspanin proteins are often expressed at 30,000-100,000 copies per cell, 
and several different tetraspanin proteins are present in almost all cell types and species 
analysed so far.  Whereas some tetraspanins are widely expressed on almost all cell 
types (for example CD81) or on most epithelial, endothelial and fibroblastic cells (for 
example CD151), others are more restricted (eg. CD137 and CD53 for lymphoid cells) 
[77]. 
 
1.4.1 Characteristics of Tetraspanins 
Tetraspanins have four transmembrane domains (TM1-TM4), forming a small and a 
large extracellular loop (SEL and LEL), with short intracellular amino and carboxy tails 
and also several conserved amino acids, including an absolutely conserved CCG motif 
and two other cysteine residues that contribute to two crucial disulphide bonds within 
the LEL.  General structural features of tetraspanin proteins are highlighted in Fig.:8. 
The tetraspanin proteins are often inaccessible to cell surface labeling reagents because 
of their diminutive stature, protruding only 4-5nm above the membrane.  
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Of the around 200-350 amino acids that are found in tetraspanins, 13-31 amino acid 
reside in the short extracellular loop (SEL), for which structural information is not yet 
available.  The large extracellular loop (LEL, 69-132 amino acids) is subdivided into a 
constant region, containing three α-helices (A, B and E), and a variable region, which 
contains nearly all of the known tetraspanin protein-protein interaction sites.  Most of 
the tetraspanins are modified by N-glycosylation; such as variably glycosylated or 
acylated, such as CD9. The glycosylation patterns between different tetraspanins vary 
widely, however some, like CD81 are not glycosylated.  CD9 contains a glycosylation 
site in SEL, whereas most other glycosylated tetraspanins contain sites in LEL. The 
first, third and fourth transmembrane domains often contain polar residues of unknown 
function, and almost all tetraspanins are modified by the post-translational addition of 
palmitate to membrane proximal cysteine residues.  Palmitoylation has a crucial 
influence in organizing tetraspanins and their neighbors into tetraspanin enriched 
microdomains (TEMs). Several features of TEMs imply that these are a new type of 
signaling platform, distinct from lipid rafts. Several tetraspanins such as CD151 have 
been physically linked to integrins, where they modulate integrin-dependent cell 
adhesion activities [77].   
CD81, a Prototypical Tetraspanin
Small Extra cellular Loop
Large Extra cellular Loop
Trans Membrane domain
Adapted from  Nature Rev. Imm. 5, 136-148 (2005)
 
Fig.:8 Schematic structure of Tetraspanin molecule 
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1.4.2 Genetic insights into Tetraspanin Functions 
Human Tetraspanins 
Mutations in four different human tetraspanins result in notable phenotypes. Several 
individual mutations in the TALLA-1/A15 tetraspanin, each within the LEL loop, lead 
to a new form of X-linked mental retardation.  However, little is known so far about the 
disease mechanism.  For mutations of the peripherin/RDS tetraspanin, though, the 
disease mechanism is clearer.  Any of over 70 different mutations in this tetraspanin 
disrupt the parallel layered structure of the outer segments of photoreceptor cells, which 
results in retinal dystrophies.  Mutations in the tetraspanin ROM1 (a rod outer segment 
protein and partner for peripherin/RDS), can also synergize with a specific 
peripherin/RDS point mutation to yield digenic retinal disease (whereby two genes 
interact to produce the disease phenotype).  Recently a disease causing mutation in 
human tetraspanin CD151 has been described.  In a rare mutation, CD151 is truncated 
and lacks its integrin binding domain.  Patients bearing this mutation have end stage 
hereditary nephritis and a type of skin blistering disease known as pretibial 
epidermolysis bullosa.  Notably, mutations of human integrin α6β4 and the mouse 
integrin α3 subunit also cause kidney disruption and/or skin blistering diseases. Human 
patients with mutations also have sensorineural deafness (irreversible hearing loss 
involving nerve damage) and β-thalassaemia minor. It is possible that the observed 
patients might also have mutations in genes other than CD151.  However, the most 
straightforward interpretation is that CD151 regulates basement membrane integrity in 
the inner ear and in bone marrow as well as in the skin and kidney [77].  
 
Mouse Tetraspanins 
In mice, the genes for seven different tetraspanins (CD9, CD81, CD37, Tssc6, CD151, 
Peripherin/RDS and ROM) have been deleted. Mice that lack the tetraspanins 
peripherin/RDS or ROM1 have severe or mild retinal degeneration, respectively, which 
is consistent with the results seen in humans.  By contrast, mice lacking CD151 are 
surprisingly different from humans that are deficient in CD151.  CD151KO mice were 
viable and fertile, their skin and kidney development was apparently normal, and there 
were no obvious alterations in the functions of their associated laminin binding 
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integrins in vivo.  Possibly, truncated human CD151 is more harmful than a deleted 
CD151 in mice because there may be opportunity for compensation by other 
tetraspanins in the complete absence of CD151. Also, it has not yet reported whether 
humans with mutant CD151 have blood clotting defects such as those seen in 
CD151KO mice [65].  CD151KO keratinocytes have significantly dimished cell surface 
levels of the tetraspanin CD9.  It is not yet known whether cell surface levels of other 
CD151 associated tetraspanins (such as CD81, CD82, CD63 and CD53) are also 
affected by the absence of CD151.  Deletion of CD151 cause hyperproliferation of T 
cells in vivo, but did cause hyperproliferation of T cell receptor stimulated T cells in 
vitro.  Deletion of the tetraspanins CD81, CD37 or Tssc6 also caused strikingly similar 
T cell hyperproliferation in vitro [63-65].  Hyperproliferation might arise from 
excessive activity of the tyrosine kinase LCK, thereby upregulating phosphorylation of 
important T cell signaling molecules.  Knockout of CD9 did not affect mouse humoral 
immune responses or T cell proliferation [66].  However, oocyte fertilization was 
impaired in CD9KO mice, owing to a deficiency in sperm egg fusion.  CD9 null mice 
also show defective myelination in the peripheral nervous system [66].  
 
1.4.3 Tetraspanins and Malignancy 
Some tetraspanins have been viewed as useful markers for the characterization of 
cancer cells.  CD9 was initially described on the surface of cells of B-lineage acute 
lymphoblastic leukaemia.  It is expressed on 90% of B lineage acute leukaemias, and 
on 50% of acute myeloid leukaemias and B lineage chronic lymphoid leukaemias.  The 
tetraspanin TALLA-1 is expressed in acute neuroblastomas and T lymphoid 
leukaemias.  CD63, the first tetraspanin to be cloned is strongly expressed at early 
stages of melanoma formation and is downregulated at advanced stages. CD82 
expression is reduced during the tumoural progression of prostate, lung, pancreas and 
colorectal cancers. Recently it has been shown that CD82 specifically interacts with an 
endothelial cell surface protein, Duffy antigen receptor for Chemokines (DARC, also 
known as gp-Fy and encoded by DARC) by Yeast two hybrid screening.  This 
interaction leads to inhibition of tumor cell proliferation and induction of senescence by 
modulating the expression of TBX2 and p21 [80]. Similarly, the level of CD9 was 
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lower in cell lines derived from metastasis of colon carcinoma as compared with cell 
lines derived from the primary tumour. Experimentally it was shown that transfection 
of CD9 or CD63 into melanoma cells induced a reduction of the metastatic potential of 
these cells. This phenomenon was also observed following the transfection of CD82 
into prostate cancer cells [74].  
 
There have been many reports showing a critical role for integrins in tumour 
development, invasion or metastasis. Therefore, a direct or indirect effect of 
tetraspanins on integrin function might lead to alterations of adhesion or migration 
properties of the malignant cells that could modify their metastatic potential. In cancer 
of the oesophagus, in which prognosis is linked to the expression of CD82, no 
mutations have been observed in the gene encoding CD82; thus downregulation is not a 
result of mutation.  It has been suggested that CD82/KAI-1 expression is 
downregulated by the p53 tumour suppressor gene but this was not confirmed by other 
reports. Despite the vast amount of work devoted to the relationship of tetraspanin 
expression with the prognosis of tumours, tetraspanins are not used as markers in 
routine practice for assessing the prognosis of cancer in patients [74]. 
 
1.4.4 Tetraspanins in Viral infections 
There is increasing evidence for the involvement of tetraspanins in infections by 
various viruses.  The most extensively documented involvement of a tetraspanin in viral 
infection is CD81 in HCV infection. CD81 was the first protein ligand identified for 
HCV, specifically for E2 protein. The tetraspanin CD82 was identified as an antigen 
recognized by several antibodies found to inhibit HTLV-1 mediated syncytium 
formation. Coimmunopresipitation experiments show that HTLV-1 Env glycoproteins 
interact with highly glycosylated forms of CD82. It has been shown that HIV-1 
infection is inhibited by antiCD63 antibodies, but not by antibodies to CD9 or CD81 
[78]. Feline immuno-deficiency virus (FIV) infection also appears to involve 
tetraspanin CD9.  Anti CD9 antibody has been shown to inhibit the FIV infection. 
These studies suggests that tetraspanins as the targets of antibodies which inhibit the 
infectivity of a range of viruses.  Much intense studies needs to be done in this line, the 
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major obstacle is the availability of suitable reagents for detection and stimulating 
antibodies for a range of tetraspanin molecules both for human and as well as for 
mouse. 
 
1.4.5 A role for Tetraspanins in Antigen Presentation! 
It has been shown that the tetraspanin CD82 is a resident of MHC class II compartment, 
where it associates with HLA-DR, -DM and –DO molecules [61,79].  Similarly, CD63 
also has been shown to associate with these molecules and both CD82 and CD63 
associate with each other. The ability of CD82 and CD63 form complexes with class II 
MHC, DM, and DO suggests that the tetraspanin proteins may modulate presentation, 
but so far no functional evidence has been reported.  Therefore, it was an aim of this 
thesis to study whether or not the tetraspanin CD82 would have an influence of antigen 
presentation.  
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2. Materials and Methods 
2.1: Materials: 
2.1.1:  Mice 
C57BL/6 
H2-O-/- 
mDO Tg 
anti HEL BCR Tg 
CD82-/- 
CD53-/- 
CBA/J 
OTI TCR Tg 
OTII TCR Tg 
2.1.2:  Chemicals and Reagents 
Dimethyl Sulfoxide (DMSO)    Sigma 
HEPES                 Sigma 
Ethylene diamine tetraacetic acid (EDTA)  Sigma 
Potassium chloride      Sigma 
Sodium citrate      Sigma 
Glycine      Roth 
Tris       Roth 
Magnesium chloride     Roth 
Sodium chloride     Roth 
 40 
Sodium azide      Sigma 
Bovine serum albumin (BSA)    Sigma 
Agarose      Applichem  
Polyacrylamide     Applichem 
Sodiumdodecyl sulfate (SDS)    Roth 
TEMED      Sigma 
Ethydium bromide     Roth 
Bromophenol blue     Roth 
Acetone      Roth 
Methanol      Roth 
Ethanol      Roth 
Chloroform      Roth 
Isopropanol      Roth 
Formaldehyde      Roth 
Cell strainers      Hartenstein 
Trypan blue      Sigma 
Proteinase K      SIGMA-Aldrich 
Complete Protease inhibitor    Roche 
Gene Ruler™ 100bp Ladder MBI Fermentas 
Cycloheximide Sigma-Aldrich 
ECL chemiluminescence kit Pierce 
Scintillation fluid (Betaplate Scint)             Wallac 
Nitrocellulose membrane Amersham/ 
Bioscience 
Whatman filter paper Hartenstein 
Whatman membrane for NTOC Herolab 
96 well cell culture plates Cellstar 
96 well ELISA plates Nunc 
6 & 24 well cell culture plates Cellstar 
12 well cell culture plates TPP, Switzerland 
6 mm Petri dish Cellstar 
 41 
T-25, T-75 & T-250 tissue culture flasks Greiner 
FACS tubes BD 
NBT, BCIP, anti Dig antibody Roche 
Peptides: 
 HEL peptide (34-45):  FESNFNTQATNR 
 HEL peptide (46-61):  NTDGSTDYGILQINSR 
 OVA peptide S8L:  SIINFEKL 
 OVA peptide K17G:  KISQAVHAAHAEINEAG 
2.1.3:  Antibodies 
for proliferation assay : 
αCD3ε (145.2C11)     BD Pharmingen 
αCD28 (37.51)     BD Pharmingen 
 
for ELISA: 
IL-2 ELISA       
Capture antibody JES6-1A12:             Anti-mouse IL-2 mAb 
 Detection antibody JES6-5H4:         Biotinylated anti-mouse IL-2 mAb 
Avidin-horseradish peroxidase conjugate                             Dianova 
Recombinant mouse IL-2     R&D 
Streptavidine-Eu+                  PE 
 
Cytometer setup beads    BD Biosciences 
PE positive control detector 
FITC positive control detector 
Wash buffer 
Assay diluent 
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for FACS staining: 
All antibodies were purchased from BD Pharmingen unless otherwise 
mentioned. 
Antibody   Clone 
anti-CD4 PE    (GK1.5)    
 anti-CD4 FITC   (GK1.5)  
anti-CD4 bio    (GK1.5) 
anti-CD8 PE    (53-6.7) 
anti-CD8 FITC  (53-6.7) 
anti-CD3 FITC  (145.2C11) 
anti-CD25 PE   (PC61) 
anti-TCRβ bio   (H57-597) 
anti-CD44 FITC  (IM7) 
anti-CD5 bio   (53-7.3) 
anti-CD69 bio   (H1.2F3) 
anti-CD62L bio  (Mel 14)    
anti-NK1.1 PE   (PK136) 
anti-LFA1   (HI111) 
anti-CD49 bio   (9F10) 
anti-CD18 bio   (6.7) 
anti-Fc receptor  (24G2) 
anti-Rat IgG2aκ  (R35-95)  
 
2.1.4:  Media and Buffers 
for cell culture, proliferation assay and FACS staining: 
PBS (Phosphate buffered saline): 
 8 g  NaCl 
  0.2 g   KCl 
 1.44 g  Na2HPO4 
 0.24 g  KH2PO4 
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Dissolve in 800 ml dH2O, adjust pH to 7.4 with HCl 
Volume adjust to 1 L, autoclave and store at RT 
FACS-Buffer: 
PBS + 0.1% BSA + 0.01% Azide 
 
MACS buffer: 
 
EDTA  - 2mM 
FCS  - 0.5% 
Human ply Ig - 1% in dPBS 
 
RPMI+ 1640 Medium:    Invitrogen, Karlsruhe 
+L-Glutamin (0.07%)    GIBCO 
+Na-Pyruvat (1 mM)     GIBCO 
+β-Mercaptoethanol (0.05 mM)  GIBCO  
+MEM (non essential amino acids) (1%) GIBCO 
+ Penicillin (100 U/ml),    Grunthal 
+ Streptomycin (100 U/ml) FatolGmbH  
+ FCS (Foetal calf serum) (1-10%)  GIBCO 
   (heat inactivated at 56°C for 45 min) 
 
  DC medium 
   400 ml commercial RPMI, 50ml heat inactivated (56oC, 45min) 
   filtered FCS, 50ml filtered F1/16 s/n as a source for GM-CSF,  
   1x glutamine, 1x P/S, mercaptoethanol. 
for genomic DNA isolation and agarose gel electrophoresis: 
Tail Lysis Buffer: 
50 mM Tris pH 8.0 
100 mM EDTA  
100 mM NaCl 
1% SDS 
 44 
 
 
TBE Buffer (1x): 
10.8 g Tris 
    5.5 g Boric acid 
    0.37 g EDTA 
add   1 L H2O  
DNA Loading Buffer: 
0.25% Bromophenol blue 
0.25% Xylene Cyanol FF 
30% Glycerol in water 
store at 4°C 
1% Agarose Gel: (150 ml) 
1.5 g agarose  
150 ml 1x TBE buffer 
boil  
add 4 µl Ethidium bromide (10 mg/ml) 
for ELISA 
Coating buffer (0.1 M Sodium Carbonate, pH 9.5) 
8.40 g NaHCO3 
3.56 g Na2CO3 
Volume adjusted to 1L with dH2O 
Wash buffer 
PBS with 0.05% Tween-20 
Substrate buffer 
   0.1M KH2PO4, pH ~ 6 
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Substrate solution 
OPD (1mg/ml in substrate buffer) 
Hydrogen peroxide (H2O2) 
Stop solution 
2 N H2SO4 
  Enhancement solution (from PE) 
 
for Southern blotting 
 Wash buffer: 0.5x SSC; 0.1% SDS 
 Dig buffer I :  100mM Tris/HCl (pH 7.5),150mM NaCl 
 Dig buffer II :  2% Boehringer blocking reagent with Dig buffer I 
 Dig buffer III :  100mM Tris/HCl, 100mM NaCl, 50mM MgCl2, pH 9.5 
SSC : 175g NaCl+88.2g tri sodium citrate, pH 7 
Staining solution:  Dig buffer 3 (10ml)+NBT (45ul)+BCIP (35ul) per blot. 
for cell counting 
Trypan Blue Solution: 
0.4% (w/v) Trypan Blue in PBS 
Dilute 1:10 in PBS for live cell counting 
 
ACK Lysis buffer: 
 
0.15M NH4Cl  - 8.2 g 
10mM KHCO3 - 1 g 
0.1 mM Na2EDTA - 37.2 mg 
 
Add 800 ml of DDH2O and adjust pH to 7.2-7.4 with 1N HCl and finally makeup the 
volume to 1000ml.  Sterilize by filtration with 0.2um membrane filter and store at 4°C. 
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SDS-PAGE  
Composition of SDS-Poly-acryl amide gels 
  Resolving Gel: 
     Component volumes (ml) per 12 ml gel mix 
      8%   12% 
H2O     5.52 ml  3.96 ml 
30% acrylamide mix   3.24 ml  4.8 ml 
1.5 M Tris (pH 8.8)   3.0 ml   3.0 ml 
10% SDS    0.12 ml  0.12 ml 
10% ammonium persulfate  0.12 ml  0.12 ml 
TEMED    6 µl   4.8 µl  
 
Stacking Gel: 
    Component volumes (ml) per 3 ml gel mix 
H2O     2.1 ml 
30% acrylamide mix   0.5 ml 
1.0 M Tris (pH 6.8)   0.38 ml  
10% SDS    0.03 ml 
10% ammonium persulfate  0.03 ml 
TEMED    3 µl  
 
Protein Loading Buffer (1X SDS Gel Loading Buffer): 
50 mM Tris.Cl (pH 6.8) 
100 mM Dithiothreitol 
2% SDS 
0.1% Bromophenol Blue 
10% Glycerol 
Store at -20°C 
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Gel Running Buffer: (10X) 
144.13 g Glycine 
30.3 g Tris  
100 ml 10% SDS 
volume adjusted to 1L with dH2O 
store at RT 
Protein Transfer Buffer: (10X) 
145 g Glycine 
29 g Tris 
volume adjusted to 1L with dH2O 
store at RT 
dilute 10X transfer buffer: methanol: dH2O in 1:2:7 ratio before 
use 
Ponceau S Solution: 
2 g Ponceau S 
30 g Trichloroacetic acid 
30 g Sulfosalicylic acid 
dH2O to 100 ml 
store at RT 
Dilute 1:10 in dH2O for working solution 
Blocking Solution: 
5% (w/v) nonfat dried milk in PBS/0.1% Tween 
 
   2.1.5: Radioactive Material  
3[H]-Thymidin  ICN Biomedicals 
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  2.2 Instruments and Accessories 
Agarose gel reader   Mitsubishi 
Microscope    Leica 
Multichannel pipette   CAPP 
Heat block    Hartenstein 
pH meter    Hanna Instruments 
Harvester “MACH 3”   Tomtec 
β-Counter “Micro Beta Trilux” Wallac 
Centrifuge “Megafuge 1,0R”  
and “Biofuge 13” Heraeus Instruments  
   FACScan    Beckton Dickinson 
   FACSCalibur    Beckton Dickinson 
   FACSSorter vantage SE  Beckton Dickinson 
VICTOR                                             PE  
   Ultraspec 2000, UV/Visible 
Spectrophotometer   Pharmacia Biotech 
CO2 incubator    Heraeus Instruments  
   Dynal Magnet    Dynal A.S. 
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2.3:  Methods 
2.3.1:  Isolation and cultivation of bone marrow derived dendritic cells 
(bmDC) from mouse: 
 
For the isolation of bone marrow derived dendritic cells from mouse the following 
protocol was used: 
Day 0 
- Femur and tibiae were removed from a freshly killed mouse, cleaned using paper 
tissues, and transferred into sterile ice-cold DPBS. 
 
- The bones were dipped into in ice-cold 70 % ethanol for ~30-60sec for sterilization 
purpose. 
 
- The bones were transferred into sterile ice-cold DPBS. 
- Both ends of each bone were cut with surgical scissors and the bone marrow 
flushed out with ice-cold DPBS (by using a syringe with 0.45 mm ∅ needle) into a 15 
ml Falcon centrifuge tube. 
 
- The cells were centrifuged the cells at 1500 rpm for 10min at 4oC. 
- The cells were re-suspended thoroughly but gently with 1ml DC medium to 
eliminate clumps. 9ml DC medium was added to make up the final volume to 10ml. 
 
- Avoiding the clumps in the bottom of the tube, 2 x 106 viable cells were transferred 
to 100 mm Petri dishes (bacteriological grade, not culture grade, otherwise cells will 
adhere to surface). 
 
- 10ml of DC medium was added per dish. 
- Cells were incubated at 37oC in a cell culture incubator. 
Day 3 
- 10 ml of warm DC medium was added to each plate slowly (through the edge of 
the dish). 
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Day 6  
- 10ml of cells were collected carefully from the edge of the dish and centrifuged at 
1500 rpm, for 5 min. Samples from different dishes of the same animal can be pooled. 
 
- The cell pellet were re-suspended with the same volume of pre-warmed fresh DC 
medium and 10ml were transferred back to each dish. 
 
Day 8  
- The procedure described for day 6 was repeated. 
Day 9 maturation of DCs 
- 1µg/ml LPS was added to each plate; TNF-α at a final concentration of 500 U ml-1 can 
also be used instead of LPS to maturate the bmDCs (DC can be easily activated by 
pippeting, handling, etc.  It is highly recommended to keep the DCs always on ice). 
 
- Plates were incubated for 24h at 37oC. 
Day 10 Bone marrow derived dendritic cells are ready to be used. 
- Non-adherent cells (mostly dendritic cells) were collected by washing gently the 
bottom of the dishes. Adherent cells are mostly macrophages. 
 
- Centrifuge the cells at 1500 rpm for 10min. 
- Re-suspend the cells and adjust to the desired concentration.  
 
 
2.3.2:  Estimation of total IgG and IgM levels in mouse sera: 
 
 
- Falcon 96 well ELISA plates (#353912) were coated with Goat anti mouse 
IgG+IgM (H+L) ( Cat No.: 115-005-068, from Jackson Immuno Research) 
or TNP(34)BSA/TNP(3)BSA/NP(36)BSA/NP(2)BSA at the concentration 
of 1.8ug/ml in carbonate buffer, pH:9.6. 
 
- The plates were incubated at 37°C for 1hr. 30 min. or at 4°C for over night 
 
- The plates were washed with PBS-T, 3 times. 
 
- Plates were blocked with Gelatin blocking solution for 1 hr. at 37°C or over 
night at 4°C.  The plates were then covered with plastic foil to prevent 
evaporation of the liquid. 
 
- Coated plates can be stored for min 2 months at 4°C. 
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- Sera samples were diluted with PBS-T for the measurement of Ig (starting 
dilution from 1:50 in 13 steps further dilution with PBS-T). 
 
- Purified mouse IgG (Y3) can be used as positive control at the following 
dilutions; 320 ng/ml in 1 2 dilution steps until 5 ng/ml and PBST alone 
can be used as negative control. 
 
- Standard mouse IgM (Pharmingen, # 550963) starting from 125ng/ml in 1 
 2 dilution steps until 1.95 ng/ml and PBST alone can be used as negative 
control. 
 
- 100ul of diluted test sera samples or standard IgG or IgM samples per well 
were added. 
 
- The plates were incubated for 1 hr at 37oC. 
 
- The plates were washed for 5 times with PBS-T. 
 
- 100ul of secondary antibody solution was added per well to detect either 
IgG or IgM.  For IgG detection, peroxidase conjugated secondary antibody 
anti mouse IgG-HRP was used at 1:2000 dilution in PBS-T; for IgM 
detection anti mouse IgM-HRP was added at 1:1000 dilution. 
 
- The plates were incubated for 1 hr at 37oC. 
 
- The plates were washed with PBS-T for 3 times. 
 
- 1mg/ml OPD substrate solution was prepared freshly with substrate buffer. 
Hydrogen peroxide (H2O2) was added at the concentration of 1ul/ml of 
substrate buffer. 
 
- 100ul of substrate solution per well was added, waited until the colour 
change from colour less solution to olive green.  This usually takes around 
3-10min depending on the amount of antibody in the test sample.  To avoid 
the influence of temperature on the colour development step may be 
incubate at 37oC.  At elevated temperatures like 37oC the reaction of colour 
development is faster than at room temperature. Colour development may 
start in 2-5 min. 
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- The colour development reaction was stopped by adding 25ul of 2N H2SO4 
per well.  The colour will change from green to red after the addition of a 
strong acid. 
 
- The optical density was measured at 490nm with VICTOR 96 well plate 
reader. 
 
2.3.3:  B cell/T cell/DC Isolation by using MACS: 
 
 
- Spleens or LN were isolated from mice. 
 
- The spleen was placed into a 6 cm petri dish with ice cold dPBS containing 
collagenase (1mg/ml) and DNase (100units/ml). 
 
- Collagenase and DNase buffer was injected into both ends of the spleen with 
a 1ml syringe. 
 
- The spleens were incubated for 5 min on ice. 
 
- Small fragments of spleen were made with forceps. 
 
- Cells were incubated for 20 min at 37°C. 
 
- Cells that were attached to the dish during the incubation time were 
collected with a cell scrapper.  The final volume was adjusted to 15 ml with 
ice cold MACS buffer. 
 
- The cells were passing through the 40um Nylon filter into a 50 ml Falcon 
tube in order to remove clumps.  
 
- The cells were centrifuged at 1500 rpm, 10 min at 4°C. 
 
- The cell pellet was re-suspended in 1500ul ice cold MACS buffer with 5% 
Human poly IgG (to block the Fc receptors on the cell surface).  Incubated 
for 5 min on ice. 
 
- The cells were centrifuged at 1500 rpm, 10 min at 4°C. 
 
- Re-suspend the cells in 200ul of MACS buffer. 
 
- 50ul of Biotin-Antibody cocktail was added for 50X106 cells (Approx. per 
spleen). 
 
- Mix well but gently. 
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- Incubate for 10 min at 4°C. 
 
- 150ul of MACS buffer and 100ul of Anti-Biotin Micro beads was added. 
 
- Mix well and incubate for 15 min at 4°C. 
 
- 10 ml ice cold MACS buffer was added and spin at 1500 rpm, 10 min at 
4°C. 
 
- The supernatant was removed carefully without disturbing the cell pellet. 
 
- Re-suspend cell pellet in 500ul of MACS buffer. 
 
Magnetic separation with LS column: 
 
- The LS MACS column was equilibrated with 3 ml of ice cold MACS buffer. 
 
- The cell suspension was transferred, into the column without air bubbles. 
 
- The column was washed 3 times with 3ml cold MACS buffer per each step. 
 
- The flow through consisting of B cells was saved. 
 
- Elution of the cells (T cells, DCs, Macrophages) retained in the column:   
The column was removed from the magnet and placed into a 15ml Falcon 
tube. 5 ml of ice cold MACS buffer was added and pushed with the piston to 
elute the cells from the column. 
 
- 10ml ice cold MACS buffer was added to the cells. 
 
- The cells were filtered through 0.45um Nylon filter. 
 
- The cells were counted with trypan blue staining. 
 
- The cells were centrifuged at 1500 rpm, 4°C for 10 min. 
 
- The cells were re-suspended in the volume required for the experiment. 
 
 
Important steps:  Incubation time and temperature with MACS bead are very important 
and critical.  The amount of the beads and the volume of the reaction are also very 
important. 
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Important points to be noted: 
 
- Around 60% of the cells in spleen are B cells 
- One can obtain 10-25 million CD19+ cells from one spleen depending on 
the age of the mice. 
- One may obtain 2-3 million cells CD11c+ (DCs) cells from one spleen. 
 
 
MACS beads:    Cat # 
mouse antiB220-beads - 130-049-501 - Miltenyi Biotec GmbH 
mouse antiCD19-beads - 130-052-201 - Miltenyi Biotec GmbH 
 
Collagenase-4  - C-5138 from Sigma 
DNase Type-4  - D5025  from Sigma 
 
 
2.3.4  Hapten Inhibition Assay: 
 
- Sera dilutions were prepared (1: 25 in PBST) to be tested for hapten 
inhibition assay. 
 
- Hapten (TNP-L-Lys) dilutions were prepared (40mM) from the stock 
(250mM) with PBS-T.  Serially diluted the hapten solution with PBS-T in 
12 steps. 
 
- Transfer 50ul/well of hapten solution into TNP(3)BSA coated plate.  
 
- Transfer 50ul/well of sera dilution into TNP(3)BSA plate containing hapten 
solution (50ul). 
 
- In the end sera dilution would be 1:50 and hapten concentration would be 
20mM. 
 
- Plates were incubated for 1 hr at 37oC. 
 
- Plates were washed with PBST for 3 times. 
 
- Dispense 100ul of GAM-POX-IgG Fc specific secondary antibody at the 
dilution of 1:2000. 
 
- Plates were incubated for 1 hr at 37oC. 
 
- Plates were washed with PBST for 3 times. 
 
- OPD substrate was used to develop the colour reaction and measured the 
optical density at 490nm as explained previously. 
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2.3.5  Lysis of RBC cells with ACK lysis buffer: 
 
- Cells were re-suspended (use 2 ml ACK buffer per one spleen) in ACK lysis 
buffer and incubated on ice for 5-10 min.  
  
- Centrifuge the cells at 4000 rpm for 5 min. Cell pellet should look in white 
colour. 
 
- Filter through nylon filter. 
 
2.3.6 FITC-OVA uptake assay: 
 
- BMDCs were re-suspended at the concentration of 2x106 cells/ml in complete 
RPMI BMDC. 
 
- Transfer 50,000 BMDCs per well by transferring 50ul of cell suspension per 
well into a Falcon U-bottom 96 well plate. 
 
- Transfer 50ul of FITC-OVA (concentration 2mg/ml in completer RPMI) per 
well.  
 
- Plate was incubated at 37◦C cell culture incubator for the indicated time points: 
0.5hr, 1.5, 2.5, 3.5, 4.5, 5.5, 6.5 (time in hrs) and over night. 
 
- For each time point harvest the cells and block with HuPly Ig and stain with 
CD11c-APC and measure the fluorescence intensity by FACS.  
 
- Non FITC-OVA pulsed bmDC serve as negative control.  
  
 
2.3.7 Alum precipitation of antigen: 
 
- Antigen (TNP(12)OVA/NP(12)OVA) and 10% Alum in PBS were mixed in 1:1 
ratio in an eppendorf tube. 
 
- One fifth quantity of the 6.25% Ammonia solution was added to the antigen-
alum solution. 
 
- Tube was incubated for 1hr at 4oC on ice. 
 
- Centrifuge the reaction mixture at 10000 rpm for 10 min in a cold centrifuge. 
 
- Remove the supernatant without disturbing the pale yellow pellet. 
 
- Resuspend the pellet in sterile PBS for immunization. 
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2.3.8  Southern Blotting: 
Day I Isolation of genomic DNA from mouse tail piece: 
- Add 10ul of protinaseK to 700ul of tail buffer which consists of a mouse tail 
piece in an eppendorf tube. 
- Tube was incubated for o/n at 56oC. 
- Tube was centrifuged at 13000 rpm for 5 min. 
- Removed the supernatant without disturbing the pellet. (NOTE: Genomic 
DNA attaches to mouse skin fur. While removing the supernatant it is very 
important to remove the supernatant completely). 
- Transfer the supernatant containing mouse genomic DNA into a new eppi. 
- 500ul of iso propanol was added to the genomic DNA solution. 
- Mix gently but thoroughly.  You should see a white thread like precipitated 
genomic DNA. 
- Take a glass capillary and role the genomic DNA at one end of the glass 
capillary. 
- Genomic DNA was dipped in 70% ethanol first and then into 100% ethanol. 
- Place the glass capillary consists of genomic DNA into a fresh eppi.  
- 200-300ul of double distilled water was transferred to dissolve the genomic 
DNA.  Tubes were placed at 68oC for 15 min with shaking. 
- Prepared mouse genomic DNA was stored at 4oC. 
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Day 2 Restriction digestion of genomic DNA: 
- Mix 20.5ul of genomic DNA, 3ul of 10x restriction buffer, 1.5ul of 
restriction enzyme (RE). 
- Incubate for o/n at 37oC 
Day 3 Agarose gel electrophoresis and membrane transfer setup: 
- 1% agarose gel was prepared as per the standard protocols. 
- 25ul of genomic DNA digest solution was mixed with 5ul of 6xDNA 
loading dye. 
- Dig labelled marker was loaded in one lane for MW reference. 
- Run the gel at 90V until the dye front runs for ¾ of the gel. 
- Transfer the gel into denaturation buffer and shake for 20min on a shaker. 
- Wash the gel with water. 
- Place the gel into neutralization buffer and shake for 2x15 min. 
- In the meantime soak the nitrocellulose membrane in 20xSSC. 
- Arrange the transfer setup without air bubbles as shown in M-1. 
- Let the transfer run for o/n or weekend. 
 
Fig. M-1:  Transfer setup for Southern blotting. 
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Day 4 Hybridization with probe: 
- Membrane was removed from transfer setup and let it dry by placing at 80oC 
for 2hrs. 
- Pre warm the prehybridization buffer to 65oC. 
- Membrane was placed in prehybridization buffer for 1 hr. 
- Probe solution was boiled for 10 min. 
- Remove the pre hybridization buffer and add 100ml of pre boiled probe 
solution. 
Day 5 Development of membrane: 
- Membrane was washed 3x10min at 65oC with pre warm wash buffer.  From 
this step onwards work at RT. 
- Membrane was placed for 1 min in Dig buffer 1 
- Membrane was placed for 30min in Dig buffer 2 
- Membrane was placed shortly for Dig buffer 1 
- Membrane was placed for 30min in antiDig antibody solution (1:5000). 
- Membrane was washed for 2x15min with 100ml of Dig buffer 1. 
- Membrane was washed for 2 min in Dig buffer 3. 
- Membrane was incubated in the dark without shaking in BCIP-NBT staining 
solution until you see the bands (5min to o/n). 
- Stop the colour development of bands just by washing the membrane with 
distilled water and dry the membrane between filter papers. 
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2.3.9 Mass spectrometry: 
 
Spleen cells were lysed in 1% Triton X-100 and were precipitated with Y3P conjugated 
Sepharose beads.  Peptides were eluted with 0.1% trifluoro acitic acid and were 
analysed on a Reflex III mass spectrometer (Bruker).  Peptides were identified with 
multidimensional protein identification technology, which is based on two dimensional 
liquid chromatographic fractionation followed by mass spectrometric sequencing.  
Lyophilized peptides were resuspended in 5% acetonitrile, 0.5% acetic acid, 0012% 
heptafluoro butyric acid and 5% formic acid.  Peptides were fractionated on a fused-
silica micro capillary column (100um inner diameter) packed with C18 reverse phase 
material CD18-ACE 3 um (Pronto SIL 120-3-C18 ACE-EPS; Bischoff 
Chromatography) follwed by cation exchange material (Partishere SCX; 5um particle 
size; Whatman).  A fully automated eight step gradient separation was done on an 
Agilent Technologies).  The high performance liquid chromatography column was 
directly coupled to a Finnigan LCQ ion trap mass spectrometer (Finnigan) equipped 
with a nano-LC electrospray ionization source.  Mass spectrometry in the MS/MS mode 
was done according to the manufacturer’s protocol.  Peptides were identified by using 
the SEQUEST and MASCOT algorithms against the Swiss-Prot database.  Matched 
sequences were processed. 
2.3.10 Antigen Presentation Assay and IL-2 estimation 
- Purified spleen cells/DC from mouse or BMDCs (APC) was prepared following 
the standard protocols explained in the above sections. 
- 50ul of antigen presenting cells (5x104/well) were seeded into a round bottom 
96 well plate. 50ul of T cell hybridoma cells/TCR transgenic T cells (5x104/well) were 
added to the antigen presenting cells.  In the end the ratio of antigen presenting cell to T 
cell is 1:1. 
- 100ul of serially diluted 2x concentrations of protein Ags, hen egg lysozyme 
(HEL), or ovalbumin (OVA) or peptide controls were added to the APC+T cell 
mixture.   
 60 
- The culture was maintained for 24-36 hrs at 37◦C in a 5% CO2 cell culture 
incubator.   
- After incubation 100µl of the supernatant were used for the measurement of IL-
2 by a europium-based fluorescence immunoassay by using purified anti-IL-2 mAb 
(clone JES6-1A12) and biotinylated anti-IL-2 mAb (JES6-5H4) (BD Pharmingen). 
Estimation of mouse IL-2 levels by ELISA: 
 
 
- Nunc black flat bottom 96 well plates were coated with IL-2 capture 
antibody (clone JES6-1A12) at concentration of 1.8ug/ml in carbonate 
buffer, pH:9.6. 
 
- The plates were incubated at 37°C for 1hr. 30 min. or at 4°C for over night. 
 
- The plates were washed with PBS-T, 3 times. 
 
- The plates were blocked with Gelatin blocking solution (200µl/well) for 1 
hr. at 37°C or over night at 4°C.  The plates were wrapped with plastic foil 
to prevent evaporation of the liquid. 
 
- These plates can be stored for a minimum of 3 months at 4°C without much 
loss of bioactivity. 
 
- To detect the levels of IL-2 in a cell culture supernatant isolated from an 
antigen presentation assay, 100ul of antigen presentation assay cell 
supernatant were transferred into wells of anti-mIL-2 capture antibody 
coated plate.  
 
- Purified mIL-2 standards were prepared by diluting with PBST, starting 
from 40ng/ml in 1 4 steps dilution for 10 titration steps. PBST alone in the 
12th well would serve as a background negative control for the IL-2 
detection. 
 
- The plates were incubated for 3 hrs at room temperature or for over night at 
4oC. 
 
- The plates were washed with PBS-T for 5 times. 
 
- 100ul/well of 0.25ug/ml anti mIL-2-bio antibody in PBST was added. 
 
- The plates were incubated for 2 hrs at RT. 
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- The plates were washed with PBS-T for 3 times. 
 
- 100ul/well Streptavidin-Europium in assay buffer in 1:1000 dilutions was 
added. 
 
- The plates were incubated for 45 min at RT (Note: Be sure to incubate only 
45 minutes ONLY.  Longer incubation will increase the background). 
 
- The plates were washed with PBS-T for 3 times. 
 
- 150ul of enhancement solution was added per well and the plates were 
incubated for minimum 30min at RT.  Alternatively the plates can be left at 
4oC for over night. 
 
- The fluorescence was measured with VICTOR 96 well plate reader. 
 
- Results were reported as fluorescence counts per second. 
 
 
2.3.11 T and B cell Proliferation Assay: 
T cell Proliferation Assay: 
- U-bottom 96 well plates from Falcon were coated with 5µg/ml αCD3 mAb + 
5µg/ml αCD28 mAb in PBS (100µl/well) overnight at 4◦C.  Several blank wells without 
antibody coating served as non stimulated control. 
- The wells were washed 2 times with sterile PBS with a multi channel pipette.  
- 5x104 spleen cells were seeded per well in 200µl of complete RPMI medium. 
- The plates were incubated for the indicated time points at 37◦C in a 5% CO2 
incubator for 24-96 hrs. 
- The plates were covered with plastic foil to prevent evaporation.    
- Radio labelled thymidine was added at a concentration of 1µCi/well in complete 
RMPI. 
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- 18 hrs after thymidine addition, cells were harvested and thymidine 
incorporation measured as CPM (counts per minute) by using a beta scintillation 
counter. 
- Instead of αCD3 mAb+αCD28 mAb system we have also stimulated with 
soluble ConA (5µg/ml) in complete RPMI medium for the indicated time points. 
 
B cell Proliferation Assay:  
- 5x104 spleen cells/well were seeded into a 96 well U-bottom Falcon plate in 
200µl of complete RPMI medium.  LPS was supplemented for stimulation of B cells at 
a concentration of 10µg/ml. 
- The plates were incubated for indicated time points (24-96 hrs) at 37◦C in a 5% 
CO2 incubator. 
- The plates were covered with plastic foil to prevent evaporation of the medium.   
- Radio labelled thymidine was added at the concentration of 1µCi/well. 
- 18 hrs after thymidine addition, cells were harvested to measure thymidine 
incorporation in a beta scintillation counter. 
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3.1 Results Part I:  H2-O Project 
 
As outlined in the introduction H2-O (HLA-DO in human) (DO) is a non classical 
MHC class II molecule mainly expressed in B cells and thymic epithelial cells.  In 
previous studies DO have been reported to be absent from dendritic cells, but very 
recently it has been found to be expressed also in dendritic cells both in human and 
mouse [47-48].  DO is a dimeric protein consisting of two subunits α and β. H2-Oα 
knockout mice were generated in the laboratory of Dr. Lars Karlsson [54] and kindly 
provided for our analysis.  H2-O transgenic mice which express 2-3 folds higher levels 
of H2-O were developed in our laboratory by Dr. Elena Armandola  by injecting H2-O 
α and β cDNA controlled by the Kb MHC class I promoter into the pronucleus of 
fertilized eggs from (CBA/J x C57BL/6) F1 mice [56].  Since these mice were not on a 
B6 background I have back crossed with C57BL/6 for 10 times for the present study.  
These H2-O transgenic mice were also crossed with BCR transgenic mice for hen egg 
lysozyme (antiHEL BCR Tg mice, I-Ak haplotype obtained from Dr.Lee Leserman) in 
order to bring the BCR transgene into the DO transgenic background. The rationale for 
generating these mice was to investigate the role DO in antigen presentation in a 
situation where the antigen is internalized into B cells via the BCR, in comparison to 
antigen up take via the fluid phase uptake. H2-O-/- mice are of the H-2b haplotype 
because they have been generated with ES cells from the H-2b strain 129. Since the H2-
O gene is located within the MHC gene cluster one can not obtain H-2k mice deficient 
for H2-O by breeding of H2-O-/- (H-2b) mice with H-2k haplotype mice, as the latter 
would then contribute their own H2-O genes which are linked to the H-2k genes. 
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3.1.1:  FACS analysis of H2-O-/- and mDO Tg mice 
A thorough analysis of H2-O -/- was not yet been presented.  Therefore we have 
performed an extensive analysis of H2-O-/- mice and mDO Tg mice for the surface 
marker expression profiles of cells isolated from spleen, bone marrow, lymph node, and 
thymus.  
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Fig.: RI-1  Expression profile of MHC class I and class II (top), CD4, CD8 (bottom) on spleen 
cells isolated from H2-O-/-, mDO Tg, and B6 mice. 
 
As shown in fig. RI-1 no significant difference was observed in the expression profile 
of MHC class I and II molecules and ratios of CD4 to CD8 positive splenic T cells from 
H2-O -/-, mDO Tg and B6 mice. 
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Fig.:  RI-2 Expression profiles of BCR proteins IgD and IgM on spleen cells (top) and mean 
fluorescence intensity of IgD (middle) and IgM (bottom) on CD19 positive gated cells from 
H2-O-/- (red), mDO Tg (green), and B6 (black) mice.  
 
As shown in fig.: RI-2, an about 1.5 fold increase in the number of IgD single positive 
B cells was observed in spleens from H2-O-/- mice (~13%) when compared with 
controls (~8%). This increase was observed in all 10 mice tested. We then analysed the 
level of IgD expression on CD19+ gated B cells isolated from spleen.  Surprisingly, we 
found around 20% higher expression of IgD on H2-O-/- splenic B cells.   
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In contrast, IgM expression was unaltered in H2-O-/- mice when compared with 
controls.  We next examined the early B lineage cells in the bone marrow to see 
whether is there any defect in the production of B cells in bone marrow of H2-O-/- 
mice.  Early B cells are characterized by co-expression of the markers B220 and early 
B lineage marker. 
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Fig.: RI-3 Expression profile of early B lineage cells in the bone marrow of H2-O-/-, mDO 
Tg, and B6 mice. 
 
As shown in Fig.: RI-3 there was no difference observed in early B lineage cells 
production in H2-O-/- mice when compared with mDO Tg and B6 mice.  These data 
suggest that B cell production in the bone marrow is intact in these mice.  Instead, it 
seems that the matured B cell compartment in the periphery is altered in H2-O-/- mice.   
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3.1.2 Humoral Responses 
 
3.1.2.1 Normal Levels of Immunoglobulins in mDO Tg mice 
We next investigated the normal serum levels of immunoglobulins in mDO Tg mice 
and H2-O-/- mice.   
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Fig.: RI-4 Normal levels of immunoglobulins in H2-O-/-, mDO Tg, and B6 mice sera samples 
estimated by ELISA. 
As shown in the fig.: RI-4 there are elevated IgG1 levels in H2-O-/- mice when 
compared with the control mice.  This data is in agreement with published data (x).  In 
contrast, there was no difference with regard to the other subclasses of 
immunoglobulins including IgD for which elevated levels of expression have been 
observed on B cells (Fig.: RI-2). Likewise in the mDO Tg mice we have not found any 
significant differences in titers of the normal levels of immunoglobulins when 
compared with B6 mice. 
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3.1.2.2 T dependent antibody responses to antigen 
We next investigated the H2-O-/-, and mDO Tg mice for antibody responses to the T 
dependent antigen. We choose 8-10 female mice of age 8-12 weeks from each genotype 
and immunized intraperitoneally with two different test antigens TNP(11)OVA and 
NP(12)OVA antigen with alum as an adjuvant.  In principle, in response to the 
immunization with TNP(11)OVA we may expect a minimum of three different types of 
antibodies; 1) against the hapten TNP, 2) against various ovalbumin protein epitopes, 
and 3) for the junction part of TNP-ovalbumin. In order to measure only TNP specific 
antibodies and to eliminate the ovalbumin specific antibody from our ELISA 
measurements, we choose TNP-BSA.  Since the ELISA plates were coated with TNP-
BSA, only the hapten TNP specific antibodies can bind to the ELISA plates.   
 
In order to see if DO influenced the affinity of the TNP antibodies we have coated the 
ELISA plates with TNP-BSA conjugate that carry a low or high density of TNP namely  
TNP(3)BSA and TNP(34)BSA.  Low affinity antibody should not bind to the TNP low 
(TNP(3)BSA) coated plate or bind less efficiently,  whereas both high and low affinity 
antibodies specific for TNP would bind to TNP high (TNP(34)BSA) plate.  The reason 
why only high but not less affinity antibody binds to TNP low coated plates is caused 
by the fact that on a TNP low plate the TNP epitopes are spread so far apart that the 
antibody would be able to bind with one arm or binding site only.  This results in 
monovalent binding for which high affinity is crucial.  In contrast on a TNP high plate 
which is densely covered by the TNP epitope, antibodies can bind with both arms, 
resulting in increased avidity, so that also low affinity antibodies can bind. 
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Fig.: RI-5 TNP specific IgG levels in sera samples isolated from H2-O-/-, mDOTg and b6 mice.  
IgG levels were measured by ELISA at the mentioned days of post immunization with 
TNP(11)OVA (top) and NP(12)OVA (bottom) in Alum as an adjuvant.  Levels of TNP specific 
IgG on TNP(3)BSA coated plate (top left) and TNP(34)BSA coated plate (top right); NP(2)BSA 
coated plate (bottom left) and NP(36)BSA coated plate (bottom right). Eight to 10 female mice 
of age 8-12 weeks from each genotype were used in this study. Data shown is representative of 
minimum three experiments performed. 
 
The results presented in fig.: RI-5 show a slight reduction in TNP specific antibody 
binding was observed with H2-O-/- mice on TNP low plates but not on TNP high plate.  
Suggesting that anti TNP antibodies of H2-O-/- mice are of slightly lower affinity.  In 
contrast, no differences were seen for NP specific IgG levels among H2-O-/-, mDO Tg, 
and B6 mice.  This data suggests that DO may influence the affinity of the antibody 
generated against the T dependent antigen TNP-OVA but not for NP-OVA.  A possible 
explanation for the different results is that NP antibodies may be generally of higher 
affinity than TNP antibodies. 
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3.1.2.3 Determination of affinity of antibody raised in H2-O-/- mice by 
Hapten inhibition assay 
We next investigated with a different method the affinity of the antibodies against 
TNP(11)OVA from H2-O-/- mice.  As we have shown in fig.:RI-5 there was a slight 
reduction in the TNP specific IgG binding on TNP low plate suggesting that the affinity 
of antibodies secreted by H2-O-/- mice was lower when compared with control mice.  
To find out the affinity of the antibody we performed inhibition assays with the hapten 
TNP-L-Lys.  It is known that the antibody class switching from IgM to IgG starts after 
2 week of immunization, and that the affinity of antibodies increases with time.  
Therefore, we tested sera isolated from mice days 18, 30, 34, and 42 after 
immunization. 
TNP-L-Lys inhibition assay with day 18 sera on TNP(3)BSA plate
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TNP-L-Lys inhibition assay with day 30 sera on TNP(3)BSA plate
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Fig.: RI-6a Affinity of antibody raised in H2-O-/- mice with day 18 (top) and 30 (bottom) sera samples.  
Sera dilutions were normalized by taking 1:50 for H2-O-/- and 1:80 for B6 with day 18 sample and 
with day 30 by taking 1:100 for H2-O-/- and 1:200 for B6. 
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TNP-L-Lys inhibition assay with day34 sera on TNP(3)BSA Plate
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TNP-L-Lys inhibition Assay 
with Day 42 sera sample on TNP(3)BSA Plate
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Fig.: RI-6b Affinity of antibody raised in H2-O-/- mice.  with day 34 (top) and 42 (bottom) 
sera samples.  Sera dilutions were normalized by taking 1:100 for H2-O-/- and 1:200 for B6 
with day 34 sample and with day 42 by taking 1:200 for H2-O-/- and 1:400 for B6. 
As shown in fig.:RI-6a and b, sera dilutions were normalized between H2-O-/-  and B6 
mice as indicated in the figure legend. This normalization is necessary so that both 
inhibition curves started with the same OD value.  As presented in fig.:RI-6a and b we 
have not found any differences in the affinity of the antibodies raised in H2-O-/- mice 
as compared to B6 mice.   The approximate affinity of the antibodies increased from   
3x10-7M to 7.3x10-8M from day 18 to day 42 post immunization. It is possible that the 
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small differences seen on the TNP low plate in Fig.: RI-5, top left, reflect small 
differences in the antibody titer only but not in affinity.  
 
3.1.2.4 T cell independent antibody responses 
We next investigated the T independent antibody responses by injecting the T 
independent antigen TNP(77)Ficoll. B cells responding to multimeric antigens through 
multiple interactions and, do not need T cell help.  Therefore, only IgM antibodies are 
produced, because Ig class switching does not occur. 
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Fig.: RI-6 T independent antigen responses.  Antigen TNP-Ficoll specific IgM titers were 
measured by ELISA on TNP(34)BSA coated plate.  Sera isolated from days post 
immunization as show on x axis. Five female mice were used for each group, aged 8-12 weeks 
old. 
 
No differences were observed in the T independent antigen TNP(77)Ficoll specific IgM 
titers between H2-O-/-, mDO Tg and wild type control mice (Fig.: RI-6).  The titers 
were relatively low when compared with T dependent antigen.  
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3.1.3 Antigen Presentation Assays 
 
3.1.3.1 DO inhibits antigen presentation in the early endocytic 
compartments but not in the late endocytic compartments 
Previous studies on antigen presentation by H2-O-/- B cells following fluid phase 
uptake of antigen yielded at most only very minor effects [54-55,57].  In contrast, H2-O 
overexpression and anti-sense RNA knockdown studies in mouse B cell lines clearly 
showed that DO down modulates antigen presentation [56]. Likewise, transfection of 
H2-O into a mouse sarcoma cell line showed decreased antigen presentation as 
compared to control transfectants.  These results collectively support the notion that 
H2-O can inhibit antigen presentation, likely via interference with the function of H2-
M. To further clarify the role of H2-O in the class II MHC mediated antigen 
presentation pathway, we crossed our mDO Tg mice with anti HEL BCR Tg mice 
which express a high affinity BCR (IgM and IgD) specific for the antigen HEL. The 
resulting mDOxBCR Tg mice allowed us to study the effect of DO on antigen 
presentation when the antigenic cargo is delivered into the cell via a high affinity BCR.  
Because the mDO transgene is not genetically linked to the MHC locus this 
experimental system also allow to study the impact of DO on the Ak MHC allele. So far 
previous studies on DO were mainly performed with Ab and AE MHC class II antigens 
[54-57].  
 
In an antigen presentation assay antigen presenting cells take up the antigen, process it 
in specialized cellular compartments and then present the processed epitopes via MHC 
molecules.  Upon recognition of these peptide MHC complexes T cells will be 
activated and secrete IL-2.  This secreted IL-2 can be measured by a sandwich ELISA.  
Thus, the amount of IL-2 produced is a measure of the extent of the antigen 
presentation by an antigen presenting cell.   
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Two model antigens were used i.e., hen egg lysozyme (HEL) and ovalbumin (OVA).  
Both the antigens are well studied.  Fig.:RI-11 shows the location of major epitopes in 
hen egg lysozyme. 
N terminal endC terminal end
Red: 34-45
Blue: 46-61
Yellow: 85-99
Lavender: 116-129
epitope
Hen Egg Lysozyme
 
Fig.: RI-11 Solution structure of HEL (PDB: 1GXV).  Different epitopes marked with different 
colors with PyMOL software.  The immunodominent epitope of the HEL shown in red colour 
(HEL:46-61). 
 
Previous studies have shown that the HEL epitope 33-47 is preferentially processed and 
loaded into I-Ak molecules in an early endocytic compartment.  In contrast, epitopes 
46-61 and 116-129 are preferentially processed and presented in late endocytic 
compartments.  These conclusions were based on the observation that chloroquine 
which neutralizes the acidic late endocytic compartment, impairs presentation of the 
epitope 46-61 but has no or little effect on the neutral early endocytic compartments 
[41]. The T cell hybridoma 3B11 recognizes the HEL epitope region 34-45 in an I-Ak 
restricted manner. Whereas, the T cell hybridoma 3A9 recognizes HEL epitope 46-61 
(immuno dominant epitope in an I-Ak restricted manner.  For antigen presentation mice 
were expressing both, mDO and BCR, only mDO or BCR, or wild type mice. 
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Fig.:  RI-12 DO suppress antigen presentation in the early endocytic compartments but not in the late 
endocytic compartments.  Antigen presentation was performed with 3B11 (top) and 3A9 (bottom) 
hybridomas with spleen cells isolated from corresponding genotypes as presented in the figure legend.  
HEL used as antigen.  This experiment is a representative of minimum three experiments. 
As shown in Fig.: RI-12, mDO Tg- BCR Tg+ spleen cells present the HEL epitope 34-
45 better to T hybridoma 3B11 than mDO Tg+ BCR Tg+ (upper left panel).  Likewise 
when HEL antigen was taken up by the fluid phase instead of the BCR, again the over 
expression of DO was found to down modulate presentation of epitope 34-45 to the T 
hybridoma 3B11.  Thus, irrespective of the presence or absence of BCR Tg; mDO Tg+ 
spleen cells show impaired antigen presentation when tested for presentation of the 
epitope 34-45 with the 3B11 T cell hybridoma. When presentation of the epitope 46-61 
was analysed with the T hybridoma 3A9, again much higher presentation was observed 
after uptake of antigen by the BCR as compared to fluid phase uptake (lower panels). 
However, over expression of mDO did not affect antigen presentation, irrespective of 
uptake via the BCR or fluid phase with 3A9 T cell hybridoma. When the spleen cells 
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from the different mouse strains were incubated with the cognate peptide HEL 34-45 or 
HEL 46-61 no difference in peptide presentation was observed (Fig.:RI-13) 
demonstrating that DO indeed affects antigen presentation in MHC II loading 
compartments. 
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Fig.: RI-13 Antigen presentation was performed with two different HEL specific I-Ak 
restricted hybridomas 3B11 (HEL:34-45) (top) and 3A9 (HEL:46-61) (bottom) with peptide 
controls. 
These observations suggest that DO favors antigens to be processed in late but not in 
early endocytic compartments. This makes sense in physiological context because 
primarily B cells need to respond to the antigens taken via their BCR but not via fluid 
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phase. In this way DO keeps control over antigen presentation machinery in the early 
compartments in the B cell.    
 
3.1.3.2 High levels of DO inhibits antigen presentation in bmDC 
As explained earlier expression of DO was recently found in dendritic cells (DC) both 
in mouse and human [40].  Therefore, we extended our studies to antigen presentation 
by bone marrow derived DC (bmDC) isolated from mDO Tg (Ak) mice and CBA (Ak) 
wild type mice in order to see if the elevated levels (2-3 fold) of DO suppressed antigen 
presentation in bmDC. 
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Fig.:  RI-14 Elevated levels of DO suppress antigen presentation in bmDC.  Antigen presentation was performed 
with 3B11 (top) and 3A9 (bottom) hybridomas with bmDC isolated from corresponding genotypes as presented in 
the figure legend.  HEL used as antigen.  This experiment is a representative of minimum three experiments. 
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As shown in fig.:RI-14 the increased levels of DO decrease antigen presentation in 
bmDC for both HEL epitopes 34-45 and 46-61 when compared to wild type controls. 
The impairment in antigen presentation is not as drastic as seen with BCR Tg+ mDO 
Tg+ spleen cells in Fig.: RI-12.  The compartments for the generation of HEL epitopes 
34-45 and 46-61 are not known for DC and need to be determined. When the bmDCs 
were incubated with the cognate peptide HEL 34-45 or HEL 46-61 no difference in 
peptide presentation was observed (Fig.:RI-15).   
BMDC HEL pep (34-45) 3B11
0
20000
40000
60000
80000
100000
120000
140000
160000
10
0 50 25
12
.
5
6.
25
3.
13
1.
56
0.
78
0.
39 0.
2
0.
1 0
HEL pep (34-45) (uM)
IL
-
2 
Fl
u
o
re
sc
en
ce
 
Un
its
mDO Tg
CBA
 
BMDC HEL pep (46-61) 3A9
0
10000
20000
30000
40000
50000
60000
70000
80000
10
0 50 25
12
.
5
6.
25
3.
13
1.
56
0.
78
0.
39 0.
2
0.
1 0
HEL pep (46-61) (uM)
IL
-
2 
Fl
u
o
re
sc
en
ce
 
Un
its
mDO Tg
CBA
 
Fig.: RI-15 Antigen presentation was performed with two different HEL specific I-Ak 
restricted hybridomas 3B11 (HEL:34-45) (top) and 3A9 (HEL:46-61) (bottom) with peptide 
controls. 
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To further confirm that mDO would indeed impair antigen presentation and not 
expression of surface molecules that may be important for T cell recognition, such as 
MHC II or costimulatory molecules CD40 and CD80, we next investigated the surface 
marker expression profile of bmDC isolated from mDO Tg (Ak) and CBA mice.  
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Fig.: RI-16 Surface marker expression profile of bmDC isolated from mDO Tg and CBA. 
As shown in fig.: RI-16 there is no difference in the expression profile surface markers 
on bmDC isolated from mDO Tg and CBA.  Together, it can be concluded that mDO 
down modulates antigen presentation in Ak DC. 
 
3.1.3.3 Antigen presentation in bmDC from H2-O-/- mice 
We next investigated the efficiency of antigen presentation with H2-O-/- bmDC (Ab) in 
comparison with mDO Tg (Ab) and B6 controls.  Since H2-O-/- is of Ab haplotype we 
have used ovalbumin as antigen and OT I and OT II TCR transgenic T cells as 
responders.  OTI TCR transgenic T cells recognize the OVA peptide S8L presented by 
the Kb MHC class I molecule, whereas OTII T cells recognize the OVA peptide K17G 
(OVA:323-339) presented by the Ab MHC class II molecule. 
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Fig.: RI-17 H2-O-/-(H2-Kb) or mDO Tg (H2-Kb) bmDC does not show any alteration in the 
capacity of antigen presentation when compared with B6 control.  OTI (top) and OTII 
(bottom) TCR transgenic T cells were used as responders and ovalbumin used as antigen.  
This experiment has been reproduced several times. 
 
As shown in fig.: RI-17 no differences were observed in antigen presentation by H2-O-
/- or mDO Tg bmDC of the H-2b haplotype when compared with B6 controls.  This 
suggests that DO may not be crucial for antigen presentation in Ab bmDC.  There are 
several potential explanations.  For example, it is possible that the effect of DO is MHC 
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allele specific.  Alternatively, DO may not affect the loading of the OVA peptide K17G 
on to Ab molecules, which is reminiscent of the observation that DO did not influence 
loading of the HEL 46-61 epitope onto Ak molecules (Fig.: RI-12).  The result also 
show that the presentation of the S8L epitope by the MHC class I molecules was not 
affected.  This, however, was to be expected because DO is not involved in the MHC I 
presentation pathway.   
 
When the surface marker profiles of bmDC from H2-O-/-(H2-Kb), mDO Tg (H2-Kb), 
and B6 were investigated no striking differences were observed (Fig.: RI-18), which is 
in agreement with the analysis of Ak bmDC (see Fig.: RI-16). 
Surface marker analysis with bmDC
0
100
200
300
400
500
600
700
800
900
1000
MHC I MHC II CD40 CD86 CD11c
M
 
F 
I
H2-OKO
mDO Tg
C57/BL6
 
Fig.: RI-18 Surface marker expression profile of H2-O-/-(H2-Kb) or mDO Tg (H2-Kb), and 
B6 bmDC. 
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3.2: Results Part II – CD82 Project 
 
3.2.1: Generation of CD82KO mice 
As outlined in the introduction, tetraspanin proteins form a network with other 
tetraspanin family members and various membrane proteins, including MHC class I 
and MHC class II molecules.  In order to see if the presence of tetraspanins in these 
supramolecular complexes influences antigen presentation by MHC molecules, Dr. 
Satoshi Tanaka from this laboratory has generated knockout mice for the tetraspanin 
molecules CD82 and CD53. The mouse CD82 gene is located on chromosome number 
2 and contains 9 exons. The CD82 protein consists of 266 amino acid residues and the 
molecular weight of the unmodified protein is ~29,628 Da. The post translationally 
modified CD82 protein shows a molecular weight ranging from ~40,000 to 50,000 Da.  
 
The targeting vector was constructed by replacing exons 4 and 5 by the neomycin 
resistance gene (see Fig.RII-1a) which was flanked with flp site. LoxP sites were 
introduced to flank the regions exon 4 and exon 5.  The flp site allows us to delete the 
neomycin resistant gene, if the CD82 floxed/floxed mice are crossed with flp deleter 
mice. The loxP site allows deletion of the CD82 exons 4-5 if the CD82 floxed/floxed 
mice are crossed with Cre deleter mice resulting in CD82 deletion in all cells in total 
mouse body.  If desired, CD82 can also be deleted in specific tissues when mice are 
used for crossing that express Cre recombinase selectively in those tissues.  In addition 
to the CD82 knockout mice, Dr. Satoshi Tanaka has also generated for the tetraspanin 
CD53.   
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Fig.: RII-1a: CD82 gene inactivation.  Restriction maps are shown for the wild-type CD82 gene 
locus (top), targeting vector (middle) and recombinant gene locus (bottom).  Exons are indicated as 
white boxes and un translated region was shown as dark line.  neor; neomycin resistance gene, 
loxP; lox P site, & flip; flip site.  Bam HI and Eco RI; restriction sites. 
 
As shown below in Fig.: RII-1b, there are 8 exons in mouse CD53 gene.  The loxP sites 
were introduced downstream to exon 1 and up stream to exon 6.  Thereby, exons 2 
through 5 can be deleted upon crossing CD53 floxed/floxed mouse with a Cre deleter 
mouse.  An inverted neomycin resistant gene was introduced down stream to exon 1 
and loxP site. 
                                 
Fig.: RII-1b: CD53 gene inactivation.  Restriction maps are shown for the wild-type CD53 gene 
locus (top), targeting vector (middle) and recombinant gene locus (bottom).  Exons are indicated as 
white boxes and un translated region was shown as dark line.  neor; neomycin resistance gene, 
loxP; lox P site, & flip; flip site.  BglII; restriction site. 
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Deletion of the CD82 gene in homozygous/heterozygous mutants was identified by RT-
PCR (not shown) and Southern blotting, which was also used to monitor breeding of 
the CD82-/- mice.  As shown in Fig.: RII-2, a 6 kb band was released upon CD82 
knockout mouse tail DNA digestion with BamH I as determined by agarose gel 
electrophoresis, whereas a wild type mouse tail DNA released a 8 kb band. 
CD82-/- CD82+/+ CD82+/-
6 kb
8 kb
 
Fig.: RII-2 Southern Blotting analysis with genomic DNA isolated from mouse tail digested with 
BamHI for CD82 KO (CD82-/-) (left), heterozygous (CD82+/-) (right) mutants in comparison with 
WT (CD82+/+) (middle). 
 
Deletion of the CD53 gene in homozygous/heterozygous mutants was also determined 
by Southern blotting and RT-PCR (data not shown).  The CD53-/- mouse have not yet 
been backcrossed to C57BL/6 or CBA. Therefore in this thesis I focused the analysis 
mainly on CD82-/- mice.  A small portion of data that is generated with non 
backcrossed CD53-/- mice and CD82-/-xCD53-/- double knockout mice will be shown 
in the later sections.  
 
The resulting CD82-/- and CD53-/- mice were born at the expected Mendelian 
frequency and raised normally under specific pathogen free (SPF) conditions at the 
animal facilities of the German Cancer Research Center.  No obvious behavioral and 
physical abnormalities were detected.  We also crossed CD82-/- mice with CD53-/- 
mice to generate double knockout mice for CD82 and CD53.  The absence of both 
CD82 and CD53 proteins did not affected the embryonic development or litter size. 
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3.2.2 FACS profiles of various cell surface markers in CD82-/- mice 
Expression levels of various cell surface markers on immune cells isolated from CD82-
/- and wild type control mice that were backcrossed 5 times to C57BL/6 mice were 
measured by FACS.  As mentioned in the previous section, tetraspanin proteins 
associate with many different cell membrane proteins including CD4, CD8, MHC class 
I and MHC class II etc.  Therefore it is possible that lack of CD82 protein may 
modulate the expression levels of various cell surface proteins.  With this objective I 
have tested various cell surface markers on cells isolated from spleen (Fig.:RII-3a and 
3b), thymus, bone marrow and lymph nodes (data not shown). 
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Fig.: RII-3a Expression levels of CD4, CD8 on CD82-/- (top left), CD82+/+ (top right) spleen cells.  
Percentage of mature B cells (CD21 and CD23 double positive) in CD82-/- (lower left) and 
CD82+/+ (lower right) in spleen.  Total percentage of cells indicated in the respective quadrant. 
 
Fig.:3a shows that CD82 deletion did not affect the percentage of CD4 T cells, CD8 T 
cells and B cells in the spleen, or the expression levels of CD4, CD8, CD21 and CD23 
surface markers on these cells.  Thus, T and B cell development appears to be normal. 
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Fig.: RII-3b  Expression levels of  class I MHC (top left), class II MHC (top right), IgM (middle 
left), IgD (middle right), CD9 (lower left), and CD81 (lower right) on spleen cells isolated from 
CD82-/- (red), CD82+/+ (green); isotype control antibody staining was shown in gray colour. 
 
Fig.RII-3b shows that there was no difference with regard to expression of MHC class I 
and class II molecules, surface IgM and IgD on B cells.  The expression levels of other 
tetraspanin proteins CD9 and CD81 were also intact. In other lymphoid organs such as 
lymph node, bone marrow and thymus also no abnormalities were detected (not 
shown). 
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3.2.3 Humoral Responses 
 
3.2.3.1 Normal levels of Immunoglobulins in CD82KO mice 
The B cell receptor (BCR) is also known to associate with tetraspanins.  To see whether 
normal endogenous levels of immunoglobulins are affected by the absence of the CD82 
protein, we have measured the endogenous levels of different sub classes of 
immunoglobulin titers by ELISA in CD82-/- mice.  The littermate CD82+/+ mice were 
used as controls.  For this study we choose female mice of age 8-12 weeks old. 
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Fig.: RII-4  Normal levels of immunoglobulins IgG1, IgG2a, IgG2b, IgM, and IgA in not back 
crossed CD82-/- mice and wild type litter mate control CD82+/+ mice as measured by ELISA.  Sera 
isolated and tested from 5 female mice of age 8-12 weeks from each genotype that were not back 
crossed at all with B6 mice. 
 
It can be seen from Fig.: RII-4 that CD82-/- mice showed around 2 folds reduced IgG2a 
levels when compared with to their littermate control mice.  No differences were 
observed for the other immunoglobulin classes. After backcrossing CD82-/- mice with 
C57BL/6 mice for 5 times we have again tested the normal levels of immunoglobulins 
to see if the results were reproducible in mice with a more homogenous genetic 
background.  
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Fig.: RII-5 Normal levels of immunoglobulins IgG1(top), IgG2a (middle) and IgG2b (bottom) in 5 
times backcrossed CD82-/-(red bars), littermate control CD82+/+ (blue bars) and C57BL/6 (black 
bars) mice.   Sera isolated and tested from 5 female mice of age 8-12 weeks from each genotype that 
were backcrossed with C57BL/6 mice for 5 times.  Data shown is representative of minimum three 
experiments performed.                                                                                     
 
Fig RII-5 continued in the next page. 
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Fig.: RII-5 continuation: Normal levels of immunoglobulins IgG3(top), IgM (middle) and IgA 
(bottom) in 5 times backcrossed CD82-/-(red bars), littermate control CD82+/+ (blue bars) and 
C57BL/6 (black bars) mice.  Sera isolated and tested from 5 female mice of age 8-12 weeks from 
each genotype that were back crossed with C57BL/6 mice for 5 times.   Data shown is 
representative of minimum three experiments performed.                                                                                   
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As shown in Fig. RII-5 that there is some variation with regard to absolute levels of 
immunoglobulins in individual mice, but we could not detect significant differences 
between CD82-/- and CD82+/+ mice and C57BL/6 mice.  The IgG2a levels were also 
comparable in the 5 times back crossed mice.  Most likely the differences in IgG2a 
levels shows in Fig.RII-4 can be attributed to the differences in the genetic back 
ground.  
 
3.2.3.2 T cell dependent antibody responses to antigen 
Next we investigated in CD82-/- mice the antibody responses to T dependent antigen 
TNP(11)OVA. We choose 8-10 female mice of age 8-12 weeks old from each genotype 
i.e., CD82-/- and CD82+/+ mice and immunized them intraperitoneally with 
TNP(11)OVA antigen with alum as an adjuvant.   
 
As explained in previous section (3.1.2.2) in principle, in response to the immunization 
with TNP(11)OVA we may expect a minimum three different types of antibodies; 1) 
against the hapten TNP, 2) against various ovalbumin protein epitopes, and 3) for the 
junction part of TNP-ovalbumin. In order to measure only TNP specific antibodies and 
to eliminate the ovalbumin specific antibody from our ELISA measurements, we 
choose TNP-BSA.  Since the ELISA plates were coated with TNP-BSA, only the 
hapten TNP specific antibodies can bind to the ELISA plates.   
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Fig.: RII-6 TNP specific IgG levels in sera samples isolated from CD82-/- and wild type mice.  IgG 
levels were measured by ELISA at the mentioned days of post immunization with TNP(11)OVA in 
Alum as an adjuvant.  Levels of TNP specific IgG on TNP(3)BSA coated plate (left) and 
TNP(34)BSA coated plate (right). Eight to 10 female mice of age 8-12 weeks from each genotype 
that were not back crossed at all with B6 mice were used in this study. Data shown is 
representative of minimum three experiments performed. 
  
As seen in Fig.: RII-6, no significant differences in TNP specific IgG antibody titers 
were observed between CD82-/- and wild type control mice. Furthermore, there is no 
detectable difference observed between TNP high and low plates (Fig.: RII-6 left). We 
conclude that lack of CD82 protein does not influence the affinity of the antibody 
generated against the T dependent antigen.  These data also mean that class switching 
from IgM to IgG in response to T dependent antigens is intact in the absence of CD82.  
Since there were no differences in titers of the antigen TNP specific antibody between 
CD82-/- mice when compared with wild type control mice, we can also conclude that 
the B cell priming is intact in the in the absence of CD82. 
 
This experiment was performed with not back crossed CD82-/- and wild type mice and 
it needs to be repeated with backcrossed mice.  Respective experiments are underway.  
 
3.2.3.3 T cell independent antibody responses 
We next investigated the T independent antibody responses by injecting the T 
independent antigen TNP(77)Ficoll. B cells respond to the multimeric T independent 
antigens through multiple interactions and, does not need T cell help.  Therefore, only 
IgM antibodies are produced, and Ig class switching does not occur.  
 93 
T indipendend Ag sera on TNP(34)BSA Plate
0
0.5
1
1.5
2
2.5
0 3 7 12 18 24
days post immu.
O
.
D.
 
at
 
49
0n
m
CD82KO
CD82WT
 
Fig.: RII-7 T independent antigen responses.  Antigen TNP-Ficoll specific IgM titers were 
measured by ELISA on TNP(34)BSA coated plate.  Sera isolated from days post immunization 
show on x axis. 
 
No differences were observed in the T independent antigen TNP(77)Ficoll specific IgM 
titers between CD82-/- and wild type control mice (Fig.: RII-7).  The titers were 
relatively low when compared with T dependent antigen because IgM is usually of low 
affinity. For this experiment 5 female mice were used for each group, aged 8-12 weeks 
old. The mice used for this experiment were not back crossed to C57BL/6 mice.  
Currently we are testing with the same antigen CD82-/- and wild type mice that were 
backcrossed to C57BL/6 for 5 times.  
 
In conclusion, CD82 has no influence on BCR triggering and subsequent antibody 
production. 
 
3.2.4 T and B cell Proliferation  
 
3.2.4.1 CD82-/- T cells are hyper proliferative 
We next investigated the proliferative responses of T cells isolated from spleens of 
CD82-/- and wild type mice upon various stimuli like αCD3+αCD28 and Con A. As 
mentioned previously it has been shown that CD82 associate with cell surface receptors 
CD4 and CD8 along with other membrane proteins. It has been also shown that human 
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CD82 delivers a co stimulatory signal in T cells [69].  The anti CD3 antibody was used 
to stimulate the T cells via the TCR, whereas the anti CD28 antibody causes a co-
stimulatory signal.  Thus, this frequently used procedure reflects the natural stimulation 
of T cell during immune responses. 
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Fig.:8 CD82-/- T cells are hyper proliferative upon αCD3+αCD28 (left) and Con A (right).  Data 
shown is representative of three individual experiments conducted with 5 times back crossed 
CD82-/-mice with C57BL/6. Similar results were obtained in all three experiments. 
 
Interestingly, CD82-/- (H-2b) splenocytes showed significantly higher proliferation 
upon stimulation with αCD3+αCD28 (5ug/ml each, soluble form).  With the mitogen 
Con A, which stimulate also through TCR components, also a higher stimulation was 
found for CD82-/- T cells. This result may suggests that the phosphorylation of key T 
cell signaling molecules, such as the TCR ζ chain and ZAP 70 is influenced by the 
CD82 protein.  The data shown in Fig.: RII-8 is a representative of three individual 
experiments conducted with 5 times back crossed CD82-/-mice with C57BL/6. Similar 
results were obtained in all three experiments. 
 
3.2.4.2 CD82-/- B cells proliferate normally  
We next examined the proliferative capacity of spleen cells following stimulation with 
LPS. The LPS acts mainly via the TLR4 membrane protein.  The role of tetraspanin 
proteins in the context of TLR signaling is not known.   
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Fig.: RII-9 CD82-/- B cells proliferate normally upon LPS stimulation.  Data shown is 
representative of three individual experiments conducted with 5 times back crossed CD82-/-mice 
with C57BL/6. Similar results were obtained in all three experiments. 
 
No significant differences were observed in the proliferative capacity as shown in Fig.: 
RII-9 between CD82-/- and wild type mice spleen cells upon LPS stimulation.  It seems 
that CD82 is not an essential protein in B cell proliferative responses. The data shown 
in Fig.: RII-9 is a representative of minimum three individual experiments conducted 
with 5 times backcrossed CD82-/- mice with C57BL/6. Similar results were obtained in 
all three experiments.   
 
3.2.5 Antigen Presentation Assays 
 
3.2.5.1 CD82-/-(H-2k) dendritic cells show impaired antigen 
presentation 
The tetraspanin molecules CD82, CD63, CD9 have been shown to interact with antigen 
presentation machinery components namely the MHC molecules and non classical 
MHC molecules HLA-DM and HLA-DO.  Dendritic cells (DC) are the most powerful 
antigen presenting cells in the immune system.  To see whether or not the tetraspanin 
molecules CD82 and CD53 would influence antigen presentation we use bone marrow 
derived dendritic cells (bmDC) from CD82-/- and wild type mice that were back 
crossed with CBA (H-2k) mice for 5 times (from now on designated CD82-/- (H-2k)).  
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Since these mice have the H-2k MHC haplotype; we were able to utilize a panel of T 
cell hybridomas that are specific for hen egg lysozyme (HEL) epitopes in an I-Ak 
restricted manner.   
 
As explained in previous section former studies have shown that the epitope 33-47 is 
preferentially processed and loaded into I-Ak molecules in an early endocytic 
compartment.  In contrast, epitopes 46-61 and 116-129 are preferentially processed and 
presented in late endocytic compartments.   
 
These conclusions were based on the observation that chloroquine which neutralizes the 
acidic late endocytic compartment, impairs presentation of the epitope 46-61 and 116-
129 but has no or little effect on the neutral early endocytic compartments [41].  
 
T cell hybridoma 3B11 recognizes the HEL epitope region 33-47 in an I-Ak restricted 
manner. The T cell hybridoma 3A9 recognizes HEL epitope 46-61 (immuno dominant 
epitope), and 2F9 recognize HEL: 116-129 in an I-Ak restricted manner.  These later 
two hybridomas have been shown to be chloroquine sensitive. PA4.8G4 recognizes the 
HEL epitope 85-99, but its sensitivity to chloroquine is not yet known.  
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Fig.: RII-11 Antigen presentation is impaired in CD82-/- bmDC (H-2k).  Antigen presentation was 
performed with two different HEL specific I-Ak restricted hybridomas 3B11 (HEL:34-45) (top left) 
and 3A9 (HEL:46-61) (top right).  Peptide controls were shown for 3B11 (lower left) and 3A9 
(lower right). 
 
As shown in Fig.: RII-11, CD82-/- bmDC present HEL ~2 folds less efficient to the  T  
cell hybridoma 3B11 than wild type control cells. In contrast, no significant differences 
were observed with T cell hybridoma 3A9. When the bmDC were incubated with the 
cognate peptide HEL 34-45 no difference in peptide presentation was observed 
(Fig.:RII-11, lower left).  
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These results suggest that CD82 support antigen presentation in the recycling 
compartment (where recycling MHC mainly capture the processed peptides) but not in 
late endo-lysosomal compartment (where de novo synthesized MHC capture processed 
peptides). In order to verify the differences seen in CD82-/- and wild type dendritic 
cells (Fig.: RII-11) we generously received additional I-Ak restricted T cell hybridomas 
specific for HEL:33-47 epitopic region, E907, A6B3,  and T cell hybridomas 
PA4.14A8; PA1.2F9 (HEL:116-129) and PA4.8G4 (HEL:85-99) from Dr.Jose Moreno 
and Dr.Dario Vignali.  
 
It can be seen in Fig.:RII-12 (in the next page); that presentation  of HEL was lower in  
CD82-/- bmDC for all these additional T cell hybridomas which recognize the HEL 
antigen 33-45 namely E907, A6.B3, and PA4.14A8. In contrast no differences were 
observed for the HEL epitope 116-129 and HEL: 85-99 specific hybridomas PA1.2F9 
and PA4.8G4 respectively.  Together, these observations suggest that there is 
impairment in the antigen processing and presentation mechanisms in the absence of 
the CD82 protein in a compartmental specific manner.  
 
The data shown in Fig.: RII-11 and 12 is a representative of minimum three 
experiments and all the three experiments. 
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In fig.:RII-3 only B and T cells had been analysed for surface markers but not DC.  
Because of the differences found in antigen presentation with bmDC, it was of interest 
to compare the expression levels of CD11c, MHC class I and class II and costimulatory 
molecules CD40 and CD86 on bmDC from CD82-/- and WT.  However, as shown in 
Fig.:RII-13 no significant differences was observed in the expression levels of above 
mentioned surface molecules in CD82-/- bmDC when compared with wild type.  Thus, 
CD82 does not modulate the surface levels of MHC II and costimulatory molecules, 
which might have explained the differences see in the antigen presentation studies. 
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Fig.: RII-13 Surface marker expression levels on bmDC from CD82-/- and wt mice as measured by 
FACS.  Mean fluorescence intensity values were plotted for CD11c, CD86, CD40, MHC II, MHC I. 
 
3.2.5.2 FITC-OVA uptake assay with bmDC 
An alternative explanation for the above shown effect of CD82 on antigen presentation 
is that CD82 may influence uptake of antigen into the antigen presenting cell bmDC. 
To test this question we performed a FITC-OVA uptake assay.  A FITC conjugated 
ovalbumin was offered to bmDC in vitro for the different time points (next page, Fig.: 
RII-14) and then the percentage of cells positive for FITC-OVA was measured by 
FACS. 
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Fig.: RII-14 FITC-OVA uptake by CD82-/- bmDC and wild type bmDC.  Percentage of bmDC 
positive for FITC-OVA measured (top) over the time period of 6 hrs and MFI values plotted 
(lower) for the same. 
 
As shown in Fig.: RII-14 after 4 hrs most DC had taken up FITC-OVA.  There was no 
difference between CD82-/- and wt DC with regard to kinetics of amount of antigen 
uptake.  In the future it needs to be determined whether or not there is a difference in 
the uptake into early endocytic compartments. 
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3.2.5.3 CD82-/-(H-2k) splenocytes do not show impairment in antigen 
presentation 
We next performed antigen presentation assays with splenocytes isolated from CD82-/- 
(H-2k) and WT mice.  Around 50-60% of the cells in spleen are B cells, whereas DC 
represents only 1-3%.   
 
Therefore in this system B cells are the major antigen presenting cells. The antigen used 
was HEL and the T cell hybridomas were the same as the ones used for the previous 
experiments with bmDC.  
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Fig.: RII-15a CD82-/- spleen cells show intact antigen presentation.  Antigen presentation was 
performed with 3B11 (HEL:34-45) (top left), 3A9 (HEL:46-61) (top right), peptide controls for 
3B11 (bottom left) and 3A9 (bottom right). 
 
Fig.: RII-15b continued in the next page. 
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Fig.: RII-15b CD82-/- spleen cells show intact antigen presentation.  Antigen presentation was 
performed with E907 (HEL:34-45) (top left), A6.B3 (HEL:34-45) (top right), PA4.14A8 (HEL:33-
45) (middle), PA1.2F9 (HEL:116-129), and PA4.8G4 (HEL:85-99) (bottom right). 
 
To our surprise we did not find an impairment of antigen presentation with CD82-/- (H-
2k) spleen cells.  Thus, the tetraspanin molecule CD82 seems to affect antigen 
presentation in a cell type specific manner, namely in DC but not in B cells. 
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3.2.5.4 Antigen presentation by CD82-/- bmDC from C57BL/6 mice 
As mentioned we have also back crossed the CD82-/- mice with C57BL/6 mice (H-2b) 
which enabled us to investigate H-2b restricted antigen presentation.  We next examined 
the efficiency of antigen presentation with bmDCs isolated from CD82-/- (H-2b) mice 
and wild type control mice.  We have used the ovalbumin as antigen and OT I and OT 
II TCR transgenic T cells as responders.  OTI TCR transgenic T cells recognize the 
OVA peptide S8L presented by the Kb MHC class I molecule, whereas OTII T cells 
recognize the OVA peptide K17G (OVA:323-339) presented by the Ab MHC class II 
molecule. 
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Fig.: RII-16 CD82-/- (H-2k) bmDC show no impairment in antigen presentation when compared 
with wild type bmDC.  bmDC with ovalbumin antigen+OTI (top left), with ovalbumin+OTII (top 
right), with S8Lpep+OTI (bottom left), and with K17G+OTII (bottom right). The data presented is 
a representative of three independent experiments performed with 5 times back crossed CD82-/- 
(H-2b) mice. 
 As shown in Fig.: RII-16, we did not observe impairment of antigen presentation with 
CD82-/- (H-2b) bmDCs when compared with WT controls.  This data is not correlating 
with the previous observation with CD82-/- (H-2k) bmDC data (Fig.RII-11 and 12). 
Possible explanations are that CD82 may influence antigen presentation in MHC 
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haplotype specific manner, or that presentation of the K17G epitope does not occur in a 
early endocytic compartment.  With regard to MHC class I mediated presentation of the 
S8L epitope; there was also no improvement to be seen. 
 
3.2.5.5 Antigen presentation by CD82-/-XCD53-/- double knockout 
bmDC 
As mentioned earlier we have also generated knockout mice for CD53 and crossed the 
CD82-/- with the CD53-/- mice in order to generate a double knockout for CD82-/- and 
CD53-/-.  I have performed a preliminary antigen presentation experiment with double 
knockout bmDC by taking ovalbumin as antigen and OTI and OTII as responder T 
cells.  These mice have the H-2b haplotype and are not back crossed to CBA (H-2k) so 
that we could not use the panel of Ak restricted T hybridomas. 
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Fig.:17 Antigen presentation experiment with bmDC isolated from CD82-/-xCD53-/- double 
knockout mice.  DKO bmDC+OVA+OTI (top left), DKO bmDC+OVA+OTII (top right), peptide 
controls with S8L (lower left), and K17G (lower right).  The data presented is a representative of 
two independent experiments performed. 
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As shown in Fig.:17, no differences were observed in the levels of antigen presentation 
between bmDC isolated from CD82-/-xCD53-/- mice when compared with wild type 
control mice.  This experiment has been reproduced two times. These results show that 
absence of two tetraspanin molecules, CD82 and CD53, does not influence the antigen 
presentation in bmDCs.  There were also no differences in the surface expression of 
MHC class I and MHC class II on spleen cells from CD53-/- mice and double knockout 
mice (Fig.:RII-18). 
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Fig.: RII-18 MHC class I and class II expression levels on spleen cells with CD53-/- and CD53+/+ 
(left); and with double knockout for CD82 and CD53 and wild type control mice (right). 
 
3.2.5.6 Self peptide repertoires of CD82-/- spleen cells 
To determine whether endogenous peptides were presented differentially in the absence 
of CD82 protein in a collaboration with Mr. Sebastian Spindeldreher and Dr. Harald 
Kropshofer, Hofmann LaRoche, Basel;  peptides were we eluted peptides from affinity 
purified MHC class II molecules from CD82-/- and CD82+/+ spleen cells.  Sequence 
analysis by a combination of two dimensional liquid chromatography and nano 
electrospray ionization tandem mass spectrometry was performed. The peptides were 
we analyzed peptides with the computer algorithms SEQUEST and MASCOT available 
on the Swiss-Port database (http://www.expasy.org/sprot/sprot-top.html).   
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Table: RII-1 
512TELNYKNTEPVLDSDIgG 2A c region
313SFPTTKTYFPHFhemoglobin alpha chain
04NDGLNHLDSLKGTFbeta 1 hemoglobin
08LRVAPEEHPVLgamma 1 Actin
48APKETTIWVSPSPILEV-CAM 1
51RHNYEGVETHTSLH-2 class II A-S beta chain
65QQLAFKQPSSAYAAFNComplement C3
47GALLLNAPVVSITQGRIL-4 induced protein 1
25KNVTELNEPLSNEERNL14-3-3 protein γ (PKC inhibitor)
34FGPYYTEPVIAGLDPKProteasome subunit β type 3
05REPDPEDAVGGSGEAEEHLLymphocyte specific protein 1
CD82WTCD82KOSequenceName of the protein
 
Table: RII-1:  Self peptide repertoires of CD82-/- spleen cells.  Peptides were eluted from affinity 
purified MHC class II molecules from CD82-/- and CD82+/+ spleen cells.  Sequence analysis by a 
combination of two dimensional liquid chromatography and nano electrospray ionization tandem 
mass spectrometry.  Peptides were analyzed with the computer algorithms SEQUEST and 
MASCOT on the Swiss-Port database.  Numbers on the right hand side indicate the incidents of 
the same peptide identified in respective genotype. 
 
As shown in Table: RII-1 some of the peptides (shown in yellow colour) were present 
larger amounts in CD82-/- mice, whereas, others were presented more in wild type 
mice (shown in green colour).  List of all peptides sequenced is shown in appendix A-I.  
This observation suggests that CD82 influences the peptide repertoire presented by 
spleen cells.  However, these are very preliminary data as not backcrossed mice were 
used for this study. This needs to be further investigated with backcrossed mice.  It 
would be interesting to perform this study with bmDC because we have now found the 
interesting differences in antigen presentation with CD82-/- mice. 
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                                                                 DISCUSSION 
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4.1 Discussion Part I – H2-O Project 
 
Published studies to date have yielded inconclusive results concerning the function of 
DO in the class II antigen processing pathway.  In vitro biochemical assays with 
purified molecules have mostly shown that the DM/DO complex is inactive in terms of 
its ability to catalyze peptide loading of class II molecules [21] suggesting that DO 
interferes with DM function.  In contrast, functional antigen presentation assays with 
cell lines expressing different levels of DO have shown that DO can promote, inhibit, 
or have no effect on MHC class II antigen presentation.  These differences may be due 
to different experimental systems and/or the antigens examined [53-59].  In vivo studies 
using H2-O sufficient and deficient mice have also failed to define a specific role for 
DO [53].  These failure and inconclusive results are is puzzling in the light of the fact 
that a major fraction of DM is always found to be tightly associated with DO.  Since 
DM is crucial for peptide loading onto MHC II molecules, one would expect to easily 
see an effect of DO, but this is not the case. 
 
For better to understanding of the biological role of DO our laboratory has generated a 
transgenic mDO mouse as a novel tool for the analysis of DO function.  This mouse 
expresses 2-3 folds higher levels of H-2O since mDO is controlled by the Kb promoter, 
all MHC class I positive cells express the H2-O transgene. Previous studies have 
utilized H2-O-/- mice and therefore assessed a role for DO in presentation by Ab MHC 
class II molecules.  The mDO (H-2k) mice enabled us to extend the analysis to another 
MHC II allele, namely Ak.  Since DO is strongly expressed in B cells, and because B 
cells usually take up antigen via their BCR we crossed the mDO Tg (H-2k) mice with 
anti-HEL BCR Tg (H-2k) mice.  With these crossed mice we wanted to study if DO 
influenced in antigen presentation when the antigenic cargo delivered into endo-
lysosomal compartments via a high affinity BCR. The HyHEL10 antibody used for the 
generation of anti-HEL BCR Tg mice [60] has an affinity of about 10-9M.  
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4.1.1 H2-O-/- mice show higher percentage of IgD+ B cells 
First we have analysed thoroughly the expression profile of various surface markers on 
cells from spleen, bone marrow, lymph node (data not shown) and thymus (data not 
shown).  For most surface antigens, the expression was normal on H2-O-/- cells, but for 
IgD we have made the surprising observation that the percentage of IgD single positive 
cells in H2-O-/- spleen is increased consistently about 1.5 fold whereas IgM positive 
cells are unaltered. Moreover, H2-O-/- B cells displayed around 20% higher IgD levels 
than wild type controls (Fig.: RI-2). A misbalance in IgD expression may be explained 
by is a defect in the early B lineage committed bone marrow cells in H2-O-/- mice. 
However, when bone marrow precursors were analysed no defect in the early B lineage 
committed compartment was observed (Fig.: RI-2). Other groups have reported that 
during the germinal center reactions IgD is strongly reduced together with DO on B 
cells [50].  Together with our findings these observations may suggests that these DO 
and IgD control each other’s expression but the link between IgD and DO expression is 
not yet understood and needs to be investigated in the future.   
 
As mentioned the other cell surface markers namely MHC class I and class II, CD4, 
CD8, CD19, CD21, CD23, CD11c, CD5, CD40, IgM, TCR alpha, CD25, and B220 
were not changed in H2-O-/-, or mDO Tg mice (Fig.:RI-1 and data not shown). 
 
4.1.2:  Antibody responses and affinity measurements 
Since B cells in H2-O-/- mice display higher levels of surface IgD we expected that 
serum IgD levels may also be increased in these mice.  Therefore we have estimated by 
ELISA the normal levels of immunoglobulins in H2-O-/-, mDO Tg and B6 mice, but 
no significant increase in IgD levels was seen in sera from H2-O-/- mice as compared 
to controls (fig.:FI-4).  The other Ig subclasses were also not altered in H2-O-/-, mDO 
Tg mice except for IgG1 in H2-O-/- mice. Elevated IgG1 levels observed in H2-O-/- 
mice in agreement with published data [54].   
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Next we immunized H2-O-/-, mDO Tg and wild type mice with T dependent and T 
independent antigens together with the adjuvant alum.  We have selected two T 
dependent antigens for immunization i.e., TNP(11)OVA and NP(12)OVA. TNP(3)BSA 
and TNP(34)BSA conjugates were used to compare the relative affinity of the anti TNP 
sera. When the anti TNP sera were analysed there was no difference in antibody titers.  
However, we observed a decreased affinity in the TNP sera from H2-O-/- mice.  The 
decrease was small but reproducible in several experiments. For the antigen NP-OVA 
no differences with regard to affinity was found. (Fig.: RI-5 bottom).  A possible 
explanation is that NP antibodies are so called germ line antibodies which may already 
have a fairly high affinity. 
 
When we analyzed sera obtained by immunization with the T independent antigen TNP 
– Ficoll,  no  significant differences were   observed in the IgM   titers between    H2-O-
/- , mDO Tg and wild type control mice (Fig.: RI-6). 
 
When we attempted to confirm the different affinities of the anti TNP sera from H2-O-
/- mice by another method, namely inhibition by the hapten TNP-L-Lys, as shown in 
Fig.: RI-7 an increase in affinity was observed with time after immunization from 3x10-
7M on day 18 to 7.3x10-8M on day 42.  However, with the hapten inhibition method no 
difference in the affinity of TNP antibodies from H2-O-/- and wild type mice could be 
found.  The reasons for the discrepancy are not clear, but we have to keep in mind that 
the differences observed with the TNP low/high technique were very small to start 
with. 
 
4.1.3:  DO inhibits antigen presentation in early but not late endocytic 
compartments 
Comparative analysis of antigen presentation by H2-O-/- and wild type B cells 
following fluid phase uptake of antigen showed that most antigens were presented 
equally well [54-55].  In contrast H2-O over expression and anti sense RNA 
knockdown studies in mouse B cell lines have shown that DO downmodulates antigen 
presentation [56].  
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Using the mDOxBCR mice we have studied the antigen intake via a high affinity BCR 
into the B cell that express different levels of DO. As expected, uptake of HEL antigen 
via the BCR led to more efficient presentation of antigen than fluid phase uptake (Fig.: 
RI-12).  DO was found to downmodulates presentation, irrespective of the pathway of 
antigen uptake (via BCR or fluid phase).  However, only presentation of those epitopes 
was downmodulated that are loaded onto Ak molecules in early endocytic 
compartments, whereas presentation of epitopes in late compartments were not 
affected. Why should DO downmodulate antigen presentation only in early but not late 
compartments? The following potential explanation can be provided.  A BCR binding a 
antigen which has low affinity is likely to loose this antigen following internalization 
already in the early endocytic compartment.  Furthermore, BCRs for antigens are 
expected to be of low affinity because high affinity B cells with self reactivity will be 
deleted. Therefore, these antigens may be preferentially delivered to early 
compartments by the low affinity BCR.  Since the immune system is trying to avoid the 
presentation of auto antibodies, it makes sense that there is a mechanism preventing 
presentation in the early compartments [31].  This is one of the reasons why we have 
studied the affinity of anti TNP antibodies.  Our results were, unfortunately 
inconclusive and therefore neither support nor disprove this hypothesis.  Sera against 
more antigens need to be tested.  In addition, antigen presentation following uptake by 
BCRs with high and low affinity should be compared. 
 
4.1.4 High levels of DO inhibits antigen presentation in bmDC 
We extended our studies to bmDC isolated from mDO Tg (Ak) mice and CBA (Ak) to 
see whether or not elevated levels of DO would also suppress antigen presentation in 
DC.  Indeed, high levels of DO suppress antigen presentation in bmDC, but in contrast 
to B cells suppression was seen for both HEL epitopes 34-45 and 45-61. It needs to be 
tested whether these epitopes are generated in the early or late compartments in 
dendritic cells. When the bmDCs were incubated with the cognate peptide HEL 34-45 
or HEL 46-61 no difference in peptide presentation was observed (Fig.:RI-15).  Surface 
markers on bmDC were not changed, indicating that suppression of antigen 
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presentation in DC is indeed caused by DO and not by indirect changes in the 
interaction between DC and T cells. 
 
We also investigated the efficiency of antigen presentation with H2-O-/- (Ab) bmDC 
using taking ovalbumin as an antigen and OTI and OTII as responder T cells.  
However, there was no influence on antigen presentation was observed.  One 
explanation is that DO may be modulate antigen presentation in an MHC II allele 
specific manner.  Another possible reason could be DO does not affect the ovalbumin 
derived epitope. The use of OTI TCR cells shows that DO does not affect cross 
presentation or MHC class I mediated presentation. In this experimental system the 
ovalbumin epitope S8L is generated in the cytosol via cross presentation and presented 
by MHC class I molecule at the cell surface.  Since for cross presentation antigen is 
first taken up by the endocytic pathway and then fed into the MHC I pathway by a not 
fully understood mechanism, it is possible that DO would interfere with cross 
presentation but that was not found in our study.  
 
How does a two fold increase in DO affect antigen presentation? It has been shown that 
around 60-70% of DM is associated with DO.  The remaining 30-40% of DM appears 
to be free and may be the fraction that supports antigen presentation.  An increase in 
DO would decrease the fraction of free DM.  However, we have to keep in mind that 
the stoichiometry of DM:DO association is not clear,  whether it is a 1:1 association or 
whether one DM molecule is occupied by several DO molecules  
 
It is possible that more than one DO molecule binds to a DM molecule and thereby 
interferes with its activity.  The observation, however, that an about two fold increase 
of DO expression substantially inhibits antigen presentation both in spleen cells and 
bmDC, suggests the existence of a fraction of free DM molecules, which can be bound 
by additional DO molecules because DO binds very tightly to DM and dissociation has 
not been found to occur under physiological conditions, it is questionable, whether DO 
associates in vivo and occupies the next free DM molecule.  Whatever the 
stoichiometry, at first sight it does not seem to make sense that a substantial fraction of 
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DM is continuously occupied and blocked.  However, if one considers that inhibition of 
DM by DO functions only at around neutral pH in the early endocytic compartments, 
then this makes sense, because as in chapter 4.1.3 the immune system may want to 
inhibit peptide loading only in early but not in late compartments. When considering 
function and stoichiometry of DO:DM complexes, it should be kept in mind that in 
loading compartments MHC class II, DM and DO are embedded in super complexes, 
containing various tetraspanin molecules such as CD63, CD81, and CD82, which may 
influence the activity of DM:DO complex as will be discussed in the following section.  
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4.2: Discussion Part II: CD82 Project 
 
The involvement of tetraspanin proteins in various cellular processes is well 
recognized, but poorly understood.  In this study we have concentrated on the 
tetraspanin CD82. It has been shown that CD82 interacts with several transmembrane 
molecules including TCR, BCR, CD4, CD8, MHC class II, MHC class I and non 
classical MHC proteins DO and DM [61]. The interaction of CD82 with   MHC class 
II, MHC class I and non classical MHC proteins DO and DM is of particular interest 
because it occurs in endocytic compartments where antigen processing and loading of 
peptides into MHC molecules is known to take place.  We hypothesized that CD82 may 
play a role in antigen presentation. Therefore, we have generated knockout mice for 
CD82.  There are 9 exons in CD82 gene; from which we have deleted exons 4 and 5 
(Fig.:RII-1a).  The truncated CD82 mRNA does not seem to be stable enough to 
express the truncated protein (unpublished observations S Tanaka). The CD82 
floxed/floxed mice were crossed with Cre deleter mice in order to obtain the CD82-/- 
mice.  Deletion of CD82 gene in all tissues is not lethal.  The mice survived normally 
and gave birth at expected Mendelian ratio. This suggests that CD82 protein is not 
critical for developmental processes.  Moreover, no apparent behavioral, physical or 
anatomical abnormalities were found with CD82-/- mice and their life span seemed to 
be normal.   
 
Dr.S.Tanaka from our laboratory has also generated CD53 knockout.  There are 8 
exons in the mouse CD53 gene from which exons 2 to exon 5 were deleted (Fig.:RII-
1b) by crossing the CD53 floxed/floxed mice with Cre deleter mice.  Like with CD82, 
deletion of CD53 gene in mouse whole body is not lethal and CD53-/- mice breed 
normally with no apparent behavioral, physical or anatomical abnormalities. We have 
also intercrossed the CD82-/- with CD53-/- mice to obtain double knockout mice.  
These CD82-/- CD53-/- mice also bred normally.  This suggests that the lack of both 
tetraspanin molecules CD82 and CD53 does not affect  mouse embryonic development.   
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4.2.1: Surface marker expression pattern in CD82-/- mice is not 
changed 
The expression profile of different cell surface markers like class I MHC, class II 
MHC, CD3, CD4, CD8, TCR, CD11c, B220, CD43, NK1.1, DX5, IgM, IgD, CD21, 
CD23, CD19, CD25, CD44 and CD40 on various immuno-competent cells isolated 
from bone marrow, spleen, thymus, and lymph nodes are normal as no significant 
changes were observed in the absence of CD82 when compared with wild type cells 
(Fig.: RII-3a&b, and data not shown).  The expression levels of other members of the 
tetraspanin family CD9, CD81 are also intact in the absence of CD82 protein (Fig.: RII-
3b). Taken together, no T and B cell developmental defects both in terms of number 
and surface expression of various cell surface markers are observed CD82 deficient 
mice. Con A stimulated and LPS stimulated spleen cells show no significant differences 
in the expression profile of various T and B cell activation markers (data not shown).  
 
It has been shown that mice deficient for the tetraspanin protein CD81 have reduced 
levels of CD19, although expression of other surface markers in the B cell compartment 
was similar to that of WT mice. In CD82-/- mice there is no reduction of CD19.  We 
have also investigated various cell adhesion molecules, for example ICAM1, LFA1, 
LFA2, VCAM on the surface of B, T, and DC surface and found no significant 
differences observed in the absence of CD82 protein (Fig.: RII-3a and data not shown). 
Taken together the absence of the CD82 protein does not affect the expression of the 
many cell surface markers tested here. 
 
4.2.2:  Antibody responses in CD82-/- mice 
CD82 associates also with the BCR. To determine whether CD82 contributes to the 
regulation of the humoral immune response, the basal antibody levels of the 
immunoglobulin subclasses IgM, IgG1, IgG2a, IgG2b, IgG3, IgA were measured.  No 
differences were found between CD82-/- and CD82+/+ mice (Fig.: RII-5).  Next we 
immunized CD82-/- and wild type mice with T dependent and T independent antigens 
together with adjuvant alum.  When we analyzed the sera samples isolated post 
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immunization for the antigen specific immunoglobulins IgM (in case of T independent 
antigen TNP-Ficoll) and total IgG (in case of the T dependent antigen TNP(11)OVA) 
no significant differences were observed between CD82-/- and wild type control mice 
(Fig.: RII-6 and 7). 
 
This observation suggests that the priming of B cells for the formation of short lived 
plasma cells and production of antigen specific IgM in response to the T independent 
antigen TNP-Ficoll is independent of CD82 protein. The hapten specific IgG response 
in case of T dependent antigen TNP(11)OVA indicates that in the absence of CD82 
protein B cells can undergo T cell dependent class switching and produce normal levels 
of IgG. Moreover, we have not observed any significant differences in the affinity of 
anti TNP antibodies raised in the absence of CD82 as compared to wild type controls 
(Fig.:RII-6).   Together these observations suggest that the tetraspanin protein CD82 is 
not essential for the B cell priming and production of antibody against antigen, both in 
terms of titer and affinity. However, we have not tested suboptimal immunization 
protocols yet. The data presented in Fig.: RII-6 and 7 were performed with mice that 
have not yet backcrossed.  However we do not expect that major differences with 
regard to antibody production will appear in backcrossed mice because there were no 
differences in the endogenous levels of Ig in 5 times backcrossed mice.    
 
Other tetraspanin knockout mice have been studied with respect to humoral immune 
responses. For example, CD81-/- mice show partial impairment of responses to TNP-
KLH [64].  This is probably explained by the fact that CD81 strongly associates with 
CD19 which is required for B cell proliferation. CD37-/- mice show also an impairment 
of antibody production, but only in suboptimal immunization procedures [63]. In the 
case of CD9-/- mice there is no impairment in humoral immune responses [76].  These 
observations suggest that B cell priming is influenced by some (CD81, CD37) but not 
other (CD82 and CD9) tetraspanin molecules.  
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4.2.3:  CD82 influences proliferation of T cells but not B cells 
In agreement with the lack of influence of CD82 on antibody responses we have not 
observed an impairment in the proliferation of CD82-/- B cells after stimulation with 
the mitogen LPS which acts through the TLR4 receptor on B cells.  In contrast, when 
we analyzed the proliferative responses of T cells to Con A or antiCD3+CD28 we 
observed significantly enhanced proliferation in CD82-/- T cells (Fig.: RII-8). These 
observations suggest that CD82 may be involved in T cell signaling events. Upon TCR 
stimulation, the tyrosine kinase Lck plays a critical role in phosphorylation of key T cell 
signaling molecules, including the TCR ζ chain and ZAP 70. The natural ligand for 
CD82 was identified recently as the Duffy antigen receptor for chemokines (DARC) 
[80]. DARC is expressed in human erythrocytes and on endothelial cells lining post 
capillary venules in kidney and spleen. It has been shown that direct interaction of 
DARC with CD82 leads to inhibition of tumor cell proliferation and induction of 
senescence by modulating the expression of TBX2 and p21 [80].  This suggests that 
CD82 ligation with its natural ligand DARC induces anti-proliferative signals and is in 
line with our finding that the absence of CD82 in T cells enhances proliferation. 
 
T cells lacking the tetraspanins CD37, CD81 and Tssc6 are also hyperproliferative to 
TCR stimulation [63-66, 68]. It has been shown that CD82 and CD81 are involved in 
the formation of the immunological synapse at the site of TCR engagement [69].  
Thereby, these tetraspanin molecules may regulate T cell proliferation possibly by 
direct association with cell surface receptors that are essential for inducing proliferative 
signals or by controlling the formation of rafts responsible for proliferative events.  
 
4.2.4:  Role of CD82 protein in antigen presentation 
Since CD82 associates with MHC II in loading compartments, we hypothesized that it 
may modulate antigen presentation.  Indeed, the studies presented here show for the 
first time that the absence of a tetraspanin molecule, namely CD82, impairs antigen 
presentation.  We consider this is to be the major finding with the CD82-/- mice.  
Strikingly, the defect in antigen presentation was observed only in bmDC but not in 
spleen cells (Fig.:RII-11&12 and Fig.: RII-15) and thus appears to be cell type specific.  
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Furthermore, presentation was found to be only affected in the recycling compartment 
but not in late endo-lysosomal compartments as will be discussed below.  
 
I used two model antigens in the antigen presentation assays i.e., hen egg lysozyme 
(HEL) and ovalbumin (OVA).  Both the antigens have been well studied in various 
laboratories.  Upon uptake into endocytic compartments antigens are usually digested 
into various peptides or epitopes that can bind to MHC II molecules.  It is known that 
some epitopes are preferentially generated and loaded into MHC II molecules in acidic 
late endocytic compartments, whereas for other epitopes this occurs in the early 
endocytic recycling compartments, probably depending on protease activities present in 
these compartments.  Fig.:RII-10 shows the location of the major epitopes in hen egg 
lysozyme. Previous studies have shown that the epitope 33-47 is preferentially 
processed and loaded into I-Ak molecule in an early endocytic compartment.  In 
contrast epitopes 46-61 and 116-129 are preferentially processed and presented in the 
late endocytic compartments.  These conclusions were based on the observation that 
chloroquine, which neutralizes the acidic late endocytic compartment, impairs 
presentation of the epitope 46-61 and 116-129,  whereas it has no or little effect on the 
presentation of epitopes in the neutral early endocytic compartment such as epitope 33-
47.  Thus, the use of T cell hybridomas specific for different epitopes of HEL presented 
by the Ak molecule allowed us to determine if presentation occurs predominantly in 
early or late endocytic compartments.  In addition to T cell hybridomas specific for the 
above mentioned epitopes, we have also used the T cell hybridoma PA4.8G4 
recognizing HEL epitope 85-99, but we do not yet know its sensitivity to chloroquine.   
 
As shown in Fig.:RII-12; a 2-4 fold reduction in antigen presentation was observed in 
CD82-/- bmDC when we tested for the HEL epitope 33-47 with the specific T cell 
hybridomas E907, A6.B3, and PA4.14A8.  No significant differences were observed 
for presentation of HEL epitopes 46-61, 116-129 and 85-99.  The presentation of the 
synthetic 34-45 HEL peptides by bmDC was not affected by the absence of CD82 (Fig.: 
RII-11 and 12).  Together these results strongly suggest that CD82 specifically supports 
antigen presentation in early but not in late endocytic compartments.  Importantly, 
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when splenocytes were used, where the main antigen presenting cells are the B cells, no 
effect of CD82 were found (Fig.:RII-15).  These results indicate that CD82 exerts its 
biological function in cell type specific manner.  The mechanism is unclear.  We 
considered the possibility that CD82 may influence the uptake of antigen into endocytic 
compartments.  In a preliminary experiment we examined the rate of antigen 
internalization with CD82-/- bmDC versus wild type bmDC.  As shown in Fig.: RII-14 
the overall rates of internalization of FITC-OVA by CD82-/- bmDC and wild type 
bmDC are similar.  It will be necessary to follow the uptake of antigen into early versus 
late compartments, which I have not yet performed because of time limitations.   
 
The results discussed above show clearly that CD82 affects antigen presentation by 
MHC class II molecules. To investigate whether or not CD82 would also influence 
antigen presentation by MHC class I molecules, we made use of the TCR transgenic 
OT-I mice which recognize the ovalbumin-derived peptide SIINFEKL presented by the 
MHC class I molecule Kb. No difference in the presentation of SIINFEKL was 
observed between CD82-deficient and wild-type bmDC.  This result is not completely 
unexpected, as in the MHC class I antigen presentation pathway the peptides are 
generated in the cytosol and then transported by TAP into the ER where they are loaded 
on MHC class I molecules with the help of a loading complex. CD82 is not part of the 
class I loading complex, which, therefore, may explain why CD82 has no influence on 
MHC class I loading. However, it has been reported that in addition to this major TAP-
dependent pathway MHC class I may also be occasionally loaded with peptides in the 
recycling endosomal compartment by exchange of peptides. Since CD82 is found 
associated with MHC class I in endosomal compartments, it is possible that it may also 
influence peptide exchange by class I molecules in these compartments. This question 
will have to be addressed in the future. 
 
For ovalbumin, there exists another TCR transgenic mouse, designated OT-II, which 
recognizes the OVA peptide 323-339 presented by the MHC class II molecule Ab. 
When bmDC were incubated with OVA, no difference was found between CD82-/- and 
wild-type cells with regard to presentation of the OVA epitope 323-339 to OTII T cells. 
 121 
It is not yet known, if this epitope is presented in early or late endosomal 
compartments. An alternative explanation would be that the effect of CD82 on antigen 
presentation is specific for certain MHC alleles such as Ak. Such allele specificity has 
been observed for the accessory molecule HLA-DM which was found to support 
strongly antigen presentation by some MHC class II alleles, but not by others [81].  
 
As mentioned above we have also generated CD82-/- X CD53-/- double knockout mice 
in order to see if deletion of two tetraspanins would have a more drastic effect on 
antigen presentation.  When bmDC from CD82-/- X CD53-/- mice, which are of the H-
2b haplotype and are not yet backcrossed, were tested with OTI and OTII cells for 
MHC class I and class II mediated presentation of OVA respectively.  Again no 
difference was found between knockout and wild type mice.  Thus, these results are 
similar to those obtained OVA presenting CD82-/- APC.  Backcrossing of CD53-/- 
mice to CBA (H-2k) is planned and will allow us to use the large panel of Ak restricted 
hybridomas. 
 
4.2.5: Influence of CD82 on peptide profiles. 
Early after generation of the CD82 knockout mice in our laboratory, a collaboration 
with Sebastian Spindeldreher and Dr. Harald Kropshofer, Hofmann LaRoche, Basel, 
was initiated, aiming at the question whether the absence of CD82 would modify the 
overall repertoire of peptides presented by MHC class II molecules. S. Spindeldreher 
and H. Kropshofer have developed a sensitive technique by which they could extract 
peptides from one spleen of mice and sequence a large number of peptides by nano 
electrospray ionization tandem mass spectrometry. This procedure is laborious and 
time-consuming. Therefore, the results obtained so far are preliminary, as only a small 
number of mice could be tested. Nevertheless, these results indicate that there is a 
difference in the peptide repertoire of CD82-/- versus wild-type splenocytes (Table: RII-
1) (see the peptides listed in appendix A-I). It seems that from various proteins more 
peptides are generated in CD82-/- cells, whereas from other proteins more abundant 
peptides are generated in wild-type mice. These findings suggest that CD82 affects the 
overall peptide repertoire presented by MHC class II molecules. However, we have to 
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keep in mind that the mice used for these studies were not yet back-crossed to B6. 
Moreover, there appear to be variations between individual mice because the above 
mentioned changes are not found in all mice tested so far.  A more detailed study would 
require the analysis of a much larger number of mice preferably back-crossed mice. 
Since in spleens MHC class II molecules are mainly derived from B cells, and because 
DC but not B cells were found to differ in their capacity to generate and present  certain 
epitopes, it would certainly be of interest to include DC, for comparison of  the peptide 
repertoires of CD82-/- and wt DC. 
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Peptides sequences from CD82 knockout spleen cells 
Sequence Epitope
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Abbreviations 
 
Ab      antibody 
Ig      immunoglobulin 
Ag      antigen 
APC      antigen presenting cell 
BSA      bovine serum albumin 
CD      cluster of differentiation 
cRPMI-1640     complete RPMI-1640 medium 
CTL      cytotoxic T-lymphocyte 
DC      dendritic cell 
BM      bone marrow 
Thy      thymus 
bmDC      bone marrow dendritic cell 
HEL      hen egg lysozyme 
OVA      ovalbumin 
pep      peptide 
spl      spleen 
mDO      mouse DO (H2-O) 
ELISA      enzyme linked immunosorbent assay 
FACS      fluorescence activated cell sorting 
FCS      fetal calf serum 
FSC      forward scatter 
IFN-γ      interferon gamma 
IL      interleukin 
ko      knockout 
LFA-1      leukocyte function antigen-1 
LEF-1      lymphocyte enhancer factor-1 
MHC      major histocompatibility complex 
NK cell     natural killer cell 
o/n      over-night 
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PBS      phosphate buffered saline 
PI      propidium iodide 
RAG1      recombinase activating gene-1 
RT      room temperature 
TCR      T-cell receptor 
Tg      transgenic 
Th1      T helper type 1 
Th2      T helper type 2 
TNF-α      tumor necrosis factor α 
WT      wild type 
ZAP70      zeta associated protein 70 
 
